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INTRODUCTION 
 
Hepatitis E virus (HEV) belongs to the family Hepeviridae containing the only genus 
Hepevirus. It is a non-enveloped virus with a positive sense RNA of 7.2 Kilo bases 
surrounded by a capsid protein. The genome of HEV comprises of three open reading 
frames (ORF), which codes for the non-structural proteins (enzymes required for viral 
synthesis) and structural proteins (viral capsid)(1).  
The global estimate of HEV infection is 20 million, with over 3.3 million acute cases 
and 56,600 hepatitis E-related deaths annually(2).  
It majorly consists of four genotypes with both anthropologic and zoonotic affinities. 
They are widely distributed among the developing and developed countries of the 
world(3).  
Genotypic prevalence, host specificity and environmental sanitation plays a vital role 
in the distribution and clinical presentation of HEV infection.  
In the developing countries, HEV infection presents as acute illness, transmitted by 
feco-oral route affecting mostly the adolescent and adults. It has been associated with 
several outbreaks in India(4). 
In the developed countries, HEV presents as sporadic cases with a zoonotic mode of 
transmission. Chronic or persistent infections are seen in contrast to acute cases in the 
developing world especially in immunosuppressed patients (5). 
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Clinical presentation of HEV include both hepatic and extra-hepatic manifestations of 
the disease. Symptoms vary from asymptomatic presentation to fulminant liver failure. 
HEV has been well known to cause infection and increased mortality among pregnant 
women particularly from the developing regions of the world(6).  
A clinical entity named acute on chronic liver failure (ACLF) is of utmost importance 
since HEV have been attributed to acute decompensation of a chronic liver disease 
leading to liver cell failure and increased mortality(7).  
Laboratory diagnosis of HEV includes direct and indirect methods. Detection and 
quantification of HEV RNA from clinical specimens have been in use. Antigen 
detection can be done with the capsid protein (ORF 2 protein) as target using an 
Enzyme Linked Immuno Sorbent Assay (ELISA)(8).  
Indirect methods include antibody detection assays for IgG and IgM. IgG antibody 
assays are used in seroprevalence studies while the IgM antibody assays can be used 
in the diagnosis of acute HEV infection. These can be an IgM detection or an IgM 
capture (µ-capture) ELISA.  
Immune response to HEV plays a crucial role in the elimination of the virus as 
evidenced by spontaneous recovery of HEV among transplant recipients when their 
level of immunosuppression is reduced(9).   
Recent studies have been carried out on therapeutic options for the treatment of HEV 
in patients with solid organ transplants (SOT), bone marrow transplant and ACLF.   
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A 3 months therapy with 600mg of ribavirin has shown viral clearance among 
SOT(10). The efficacy of ribavirin in ACLF cases are still in trial but with promising 
outcomes(11).   
Prevention of HEV can be achieved to an extent with clean and safe drinking water, 
proper hygiene and awareness through health education. Recently a recombinant 
vaccine (Hecolin®) containing vector expressed capsid protein was licensed for use in 
humans in China, having a good long term efficacy(12). 
HEV has been recognized for nearly 30 years, yet it is unique in its features with a 
distinct geographic distribution and genotypic variation. The time of presentation 
determines the selection of appropriate assays for the detection of HEV. Its varied 
clinical manifestation sometimes posts difficulties in diagnosis of HEV.   
The role of direct and indirect markers in cases of ACLF is still not completely 
understood. The present study was undertaken to employ a comprehensive approach 
to diagnosis of HEV infection in case of acute on chronic liver failure.  
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AIMS AND OBJECTIVES 
 
AIM 
 
To study the role of hepatitis E virus (HEV) RNA quantification, HEV antigen 
detection and appropriate HEV IgM antibody assays in the diagnosis of HEV in acute 
on chronic liver failure (ACLF) patients. 
 
 
 
OBJECTIVES 
 
1. To standardize a quantitative HEV PCR for plasma and stool in patients with acute 
on chronic liver failure (ACLF).  
2. To evaluate the role of a HEV antigen detection ELISA in plasma and stool as a 
cost- effective alternative to HEV RT PCR in ACLF patients  
3. To assess and compare the role of two different IgM anti HEV antibody detection 
ELISAs in ACLF patients.   
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REVIEW OF LITREATURE 
1. Viral discovery 
A new viral etiological agent causing jaundice had been suspected nearly 35 years ago 
following a large outbreak of hepatitis among adults in the Kashmir valley in 
1978(13). On further investigation, the infection was found to be water borne 
transmission (enterically transmitted). Sera obtained from such cases failed to react 
with standard tests for hepatitis A or B available at that time. Due to its unique clinical 
features and non-availability of laboratory tests for diagnosis, these infections were 
believed to be an enterically transmitted non A non B hepatitis (ET - NANB). 
Retrospective studies from previous similar outbreaks from Delhi (1955-56) and 
Ahmedabad (1975-76) also suggested an ET - NANB.  Similar outbreaks were 
reported from Nepal, Myanmar and African countries like Sudan.  
Experiments conducted by Dr. Balayan from the Afghanistan outbreak led to 
visualization of the virus like particle for the first time with the help of immune 
electron microscopy. Following ingestion of pooled stool extracts of 9 patients from 
the epidemic, he developed clinical signs and symptoms of hepatitis accompanied by 
elevation of liver enzymes. He also visualized spherical virus like particles measuring 
27-34nm in size in his stool 28-45 days after ingestion of the stool extracts. These 
particles also reacted with the convalescent sera obtained from typical cases from the 
epidemic(14).  
Immune electron microscopy and transmission of infection to primates were the only 
means of studying the newly discovered viral etiological agent for hepatitis.  
11 
 
Animal studies on cynomolgus macaques were done by intravenous inoculation of 
stool extracts from patients and volunteers containing the virus resulted in features 
suggestive of hepatitis which were confirmed by the elevation of liver enzymes, 
excretion of particles in stool, histopathological changes and antibody response to the 
virus. Transmission to primates were used for studying the pathological changes due 
to the virus and replication of HEV, which formed the basis for understanding the 
virus. By 1990, Cloning and sequencing  part of the viral genome have been 
initiated(15).  
A new viral aetiology causing enterically transmitted hepatitis was proposed and the 
virus was later renamed as hepatitis E virus almost a decade later.  
2. Viral taxonomy  
Being an RNA virus and based on its spherical structure under the immune electron 
microscope, classification under Picornaviridae family was suggested similar to 
hepatitis A virus. Studies later confirmed that HEV was antigenically unrelated to 
picornaviruses. On the basis of morphology of the virus, HEV was classified under the 
family Caliciviridae(16).  
Further studies with phylogenetic analysis of non-structural genes of the virus 
revealed its un-relatedness to caliciviruses justifying removal from that family. HEV 
is now placed under a separate family named Hepeviridae containing the only genus 
Hepevirus.  
3. Structure of the virus  
Use of cryoelectron microscopy and three dimensional image (3D reconstruction) 
studies of the virus revealed that hepatitis E virus (HEV) is spherical and non-
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enveloped. They were observed as small round virus particles measuring about 30-34 
nanometres in size, morphologically similar to Norwalk virus and hepatitis A virus. 
HEV is larger with an indefinite surface substructures giving it an irregular surface 
resembling calyces which can be distinguishable from smooth and featureless surface 
of hepatitis A virus. In common with other hepatitis virus, HEV cannot replicate 
efficiently in cell cultures, hence further studies and characterization of the virus had 
to rely upon expression of recombinant proteins in various expression systems. 
3.1. Viral capsid: 
It is an RNA virus surrounded with a capsid protein. The capsid is coded by the open 
reading frame (ORF) 2 region of the viral genome. It is a protein made of 660 amino 
acids.  
Viral capsid helps in viral entry, interaction with heparin surface proteoglycans 
(HSPG)(17) and host cellular proteins, translocation of viral protein across the 
endoplasmic reticulum (ER), intracellular signalling and drives viral assembly. 
 It serves as an epitope for the production of neutralising antibodies and for 
development of vaccines against HEV.   
3.2. Structure of genome: 
HEV is a single stranded positive sense RNA virus. It comprises of a 7.2 Kilo base 
(Kb) genome with 3 open reading frames (ORF). It has a 5ʹ non coding region capped 
with methyl transferase (MeT) and guanyl transferase at its 5ʹ end and a poly 
adenylated tail in its 3ʹ end (Figure 1).  
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Figure 1: Structure of the HEV genome 
 
 
3.2.1. ORF 1 region: It codes for a viral non-structural protein of 1693 amino 
acids(18). It is a polyprotein with multiple functional domains. The 
sequence homology of ORF 1 region closely resembles rubella virus, beet 
necrotic yellow vein virus and the alphavirus like superfamily of positive 
sense RNA viruses.  
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The domains on the ORF 1 polyprotein are  
1. Methyl Transferase (MeT):  It catalyses the methylated capping of the 
genomic and sub genomic RNA of the virus. Only a capped genomic RNA is 
infectious and is been regarded as a protection of the virus against the host 
innate immune response.  
2. Papain like cysteine protease (PCP): These are predicted by computer 
assisted assignment of functional domains and found to be similar to the rubella 
virus protease. No functional activity has been described so far by the HEV 
protease(1).  
3. Helicase: the enzyme protein is seen in many positive sense RNA viruses and 
is essential for replication of the viral genome. The main function of helicase is 
its hydrolysis of nucleotide triphosphates (NTPase) like ATP and RNA 
unwinding activity from the 5ʹ to 3ʹ direction.  
4. RNA dependent RNA polymerase (RdRp) is an enzyme found in all RNA 
viruses. It is essential for the replication of genomic RNA from the anti-
genomic intermediate of the virus.  
5. Uncharacterised domains (X and Y domains). The X domain, is a conserved 
region, also called as the macro domain is useful in viruses that replicate in the 
cytoplasm. They may serve as ADP ribose binding modules(19) and may have 
a role in viral RNA replication and transcription(20). The Y domain is present 
about 200 amino acids downstream of MeT domain and whose function 
remains unclear.  
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3.2.2. ORF 2 region:  
It codes for the viral capsid protein. Various expression studies conducted using 
genetic engineering had shown secretion of protein with differing molecular weights. 
The nature of the protein depends on the expression system used. Post translational 
modification of these proteins like glycosylation is crucial for the epitope presentation 
and immunogenicity of the protein.  
ORF 2 region codes for a protein with 660 amino acids. Expression of ORF 2 protein 
in animal cells in culture showed secretion of 74 KDa and 88 KDa protein. 
Experiments conducted using a recombinant baculovirus expressed in insect cell lines 
secreted a 58 KDa molecular weight, N terminus truncated (111 N terminal) ORF 2 
protein along with a 50 KDa protein. These protein lacks the 111N terminus and 53 C 
terminus residues and they self-assemble into virus like particles (VLP) of 23-24 
nanometres in size(21). 
Later studies have shown that ORF 2 protein expression in E.coli cells assemble into 
structures of higher order and whose role are still yet to be explored.                                      
Mutations in the ORF 2 glycosylation site results in absence of infectious virus 
particles with a decrease in their ability to cause infection in macaque monkeys(22). 
Pulse-chase studies showed that an N terminal signal sequence translocate the protein 
into the endoplasmic reticulum (ER) for N linked glycosylation(1).  
X ray crystallographic studies of the ORF 2 protein revealed monomers of protein 
with three distinct domains. The shell (S), middle (M) and the protruding (P) 
domains(23)(24).  
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3.2.3. ORF 3 region:   
It consists of a bicistronic sub genomic RNA which codes for the viral accessory 
protein. It is made up of 114 amino acids containing two N terminal hydrophobic ends 
(D1 and D2) and two proline rich domains (P1 and P2). Expression of ORF 3 region 
in mammalian cells secreted a 13 KDa protein. Phosphorylation of these protein is 
necessary and is mediated by mitogen activated protein kinase (MAPK).  
Functions of ORF 3 protein: 
The following functions were predicted for the viral accessory protein coded by the 
ORF 3 region based on expression studies.  
1. It is an essential protein for survival of the virus and its proliferation. ORF3 
protein activates the mitogen-activated protein kinase pathways and is found to 
control the host cell milieu for viral replication. Experiments with cells 
expressing ORF 3 protein showed an up regulation of genes for mitochondrial 
Voltage dependant anion channels (VDAC) and these proteins interfere with 
the mitochondrial death signalling pathway (apoptosis) thus leading to 
prolonged intracellular survival and proliferation (25).  
2. It causes dampening of the immune response by increasing the production of 
immune suppressive factors. Increased production of alpha 1 microglobulin and 
bikunin which act as immune suppressive proteins(26). These proteins down 
regulate the expression of acute phase reactants required for inflammation and 
immune response. Raised levels of alpha 1 microglobulin is excreted in urine 
from patients with HEV infection(27). 
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3. Subcellular fractionation of the ORF 3 protein expressed in mammalian cells 
was found to be associated with cytoskeleton(28). These findings were later 
confirmed using a confocal microscope(29). The protein appears as a punctate 
and filamentous intracellular moiety which were found interacting with the 
microtubules of the cell thus affecting the cellular cytoskeleton. It is believed to 
have a role in viral egress or release. ORF 3 mutants can replicate very 
efficiently in PLC/PRF/5 or A549 cell lines(30).  
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4. Pathogenesis:  
It is a poorly understood concept but studies undertaken with novel approach 
like replication of HEV on humanized hepatocytes of chimeric mouse and propagation 
in cell lines like PLC/PRF/5 cells obtained from human hepatocellular carcinoma have 
given insights regarding the replication of HEV inside the hepatocytes. HEV appears 
to gain entry into hepatocytes through interaction with heparin surface proteoglycans 
(HSPG)(17). The intracellular movement of the virus and the mechanisms involved in 
the un-coating of the viral capsid is not completely understood. Being a positive sense 
RNA virus, the viral RNA can be directly infectious and it is translated as such in the 
cytoplasm.   
The ORF 1 region codes for a non-structural polyprotein which are then 
cleaved to form their monomeric functional units necessary for replication of viral 
RNA. The genomic RNA replicates into a negative sense RNA intermediate which 
then serves as templates for the positive sense genomic and sub genomic RNAs(31). 
The sub genomic RNA are translated into ORF 2 and ORF 3 protein. The ORF 2 
protein forms the capsid for the virus. The capsids are translocated into endoplasmic 
reticulum and are glycosylated. The viral capsid packages the genomic RNA and they 
assemble as new virions followed by the release of non-enveloped virus from the 
hepatocytes into the canalicular membrane of the bile tract. Interestingly,  the virions 
released from the baso-lateral membrane of the hepatocytes into the sinusoids contain 
an envelope derived from the host cell membrane containing ORF 3 protein through a 
possible mechanism of budding being considered(32).  
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5. Epidemiology:  
A global estimate of 20 million HEV infections, over 3.3 million acute cases and 
56,600 hepatitis E-related deaths occur annually(2). 
5.1. Geographic distribution of various Genotypes:  
HEV has a global distribution in which 4 distinct genotypes have been found. The 
genotypes have a geographic distribution. Genotype 1 is seen in North Africa, South 
and Central Asia, genotype 2 in Mexico and West Africa, genotype 3 in the North 
America, Europe and Japan while genotype 4 is seen in China and South East 
Asia(33) (Figure 2).  
Distinct epidemiological patterns exist between the developed and developing 
countries as they vary in the genotype, source of the virus, mode of transmission and 
the clinical presentation(3).  
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Figure 2: Global distribution of HEV Genotypes 
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5.1.1. Epidemiology in developing or high endemic countries: 
 Economic factors and sanitation practices plays a key role for the difference between 
distinct geographical epidemiology. Countries in Asia and Africa where genotype 1 
and 2 predominate infection is commonly transmitted through contaminated water and 
food (feco-oral route). They present as acute hepatitis affecting mostly adolescents 
and adults while children and elderly are less often infected. Outbreaks are common 
especially during rainy seasons and floods. Large outbreaks of HEV due to water 
borne transmission has been reported from endemic regions. No animal reservoirs 
have been documented.(4). Humans are considered as reservoirs. The secondary 
attack rate for HEV is 0.7-2.2% thus making person to person transmission 
uncommon unlike hepatitis A. Persistent or chronic infections have not been reported 
from these regions and the presentation is always acute in contrast to low endemic 
areas. 
5.1.2. Epidemiology in developed or low endemic countries:  
Unlike the high endemic areas, genotype 3 and 4 predominate the western world. 
Infrequent or sporadic cases of HEV have been reported in USA, Europe and Far East 
Asia. These genotypes (3 and 4) can cross species barrier and can infect a wide range 
of hosts naturally. Animal reservoirs like pigs, wild boar and deer are seen as a routes 
of  zoonotic transmission by consumption of undercooked meat or through close 
contact with infected animals(34). The virus has been isolated even from frozen meat. 
Infections tend to be in apparent among adults yet can become symptomatic in elderly 
people with underlying comorbidities.  
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6. Transmission:  
Different modes of transmission are seen among HEV which may vary depending 
on the geographic location and the circulating genotypes. They are  
1. Feco-oral route: Faecal contamination of drinking water has been associated 
with large outbreaks and sporadic cases in developing countries with poor 
sanitation and access to drinking water(4).   
2. Zoonotic transmission by consumption of undercooked meat (pigs, deer and 
even shell fish) seen mostly in developed western countries(35).  
3. Transmission through blood and blood products is now an increasing 
concern and highlights the need for screening for HEV(36).  
4. Vertical transmission from mother to child with reports indicating higher 
mortality in mother and foetal complications(37)(38).  
The latter two routes are much less frequent. 
7. Clinical features: 
The incubation period for HEV is 4-5 weeks in healthy volunteers while they can be 
variable from 2-10 weeks during outbreaks(39). Asymptomatic infections are common 
in HEV. Anicteric hepatitis in which there is mild liver damage without any clinical 
jaundice. Acute icteric hepatitis which often begins with a non-specific prodromal 
symptoms like fever, anorexia, general malaise, nausea and vomiting resulting in 
clinical jaundice in a week as evidenced by a rise in the bilirubin levels and elevated 
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transaminases (Alanine transaminase and Aspartate transaminase) which often 
resolves spontaneously in 4-6 weeks.  
Progression to acute liver failure may occur in 0.5-4% of HEV cases which may 
present with hepatic encephalopathy, coagulation abnormalities requiring ICU care 
and carries a higher mortality(40).  
Chronic HEV infection is defined as detection of HEV RNA for more than 6 months 
in serum or stool. It is associated with elevated serum transaminases and histological 
evidence of chronic liver damage of which 10% of them may progress to cirrhosis(9). 
It is established in immune suppressed individuals like solid organ transplant, HIV 
individuals, haematological malignancies like leukaemia and bone marrow transplant 
recipients leading to chronic liver failure(41).  
Chronic HEV infection in immunosuppressed particularly solid organ transplant 
recipients with a genotype 3 HEV infection may show a rapid progression to liver 
failure without treatment. Among the solid organ transplants, usage of tacrolimus for 
immune suppression and thrombocytopenia have been associated with persistent 
chronic HEV infection. In patients who had under gone liver transplant, HEV is 
associated with post-transplant hepatitis progressing to cirrhosis and liver failure 
requiring liver re transplantation(42).  
In patients with pre-existing liver disease of any aetiology (infective or non-infective), 
acute decompensation of liver disease occurs due to superadded HEV infection 
leading to increase in mortality. A condition now known as ACLF in which HEV can 
be a causative agent for acute decompensation of pre-existing liver disease(43)(7). 
The various presentations of HEV have been referred in Table 1.  
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Table 1: Spectrum of clinical presentation of HEV 
 Clinical Manifestations of HEV  
1. Asymptomatic infections  
2. Anicteric hepatitis  
3. Acute icteric hepatitis  
4. Acute liver failure (ALF) 
5. Chronic HEV infection 
6. Acute on chronic liver failure (ACLF) 
7. Extra-hepatic manifestations  
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7.1. Extra-hepatic manifestation:  
Occasionally neurological manifestations involving both central and peripheral 
nervous system like meningoencephalitis, transverse myelitis, aseptic meningitis, 
peripheral neuropathy, Guillian Barre syndrome, cranial nerve palsies(44), along with  
renal involvement like membranoproliferative and membranous glomerulonephritis 
especially with genotype 3 HEV among solid organ transplants on 
immunosuppressive drugs can occur(45). Case reports of acute pancreatitis in patients 
with HEV genotype 1 infection have been reported involving men more 
frequently(46).  
Haematological abnormalities like aplastic anaemia and haemolysis are also reported. 
Case reports with thrombocytopenia due to immune mediated platelet destruction have 
been documented(47).  Autoimmune manifestations include immune 
thrombocytopenia, Henoch-Schonlein purpura(48), arthralgia and skin rashes(49).  
7.2. HEV in pregnancy: 
In hyper-endemic regions, pregnant women are at a greater risk of developing 
fulminant hepatic failure with increased mortality(50). HEV prevalence of 37-86% (P 
Kar et al 2012) is observed in pregnant women, more so in the 2nd and 3rd trimester. 
The mortality associated with HEV in pregnancy varies from 3.4-73%(38) in studies 
from India with an increase in the third trimester (44.4%) (51). A recent study from 
India showed a maternal mortality of 20.5% (Jethwa D K et al 2015) 
It is associated with maternal complications like miscarriage and antepartum 
haemorrhage and poor foetal outcomes like intrauterine death, still birth, premature 
delivery, neonatal hypoglycaemia and death(52).   
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8. Laboratory diagnosis: 
  A variety of assays had been made available since the discovery of the virus for 
the detection of antibodies in the serum, antigens in both plasma and stool and the 
nucleic acid detection methods in plasma, stool and bile.  
The methods used for detection of HEV depends on the clinical symptom and the time 
of presentation of the patient (Figure 3), cost and competency level of the laboratory 
and are listed below as Table 2.  
Table 2: Laboratory methods used in diagnosis of HEV 
Direct methods Indirect methods 
RNA detection methods  
Conventional reverse transcriptase PCR 
Real time PCR 
Loop mediated isothermal 
amplification (LAMP) 
IgG antibody detection assay (ELISA) 
IgM antibody detection assay (ELISA) 
- Antibody detection 
- Antibody capture  
Antigen detection assays (ELISA) 
 
Rapid tests 
- Immuno-chromatography tests 
(ICT) for IgM, IgG detection or 
both.  
Virus culture and electron microscopy 
Immune electron microscopy  
Fluorescent blocking antibody assays 
Western blot  
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8.1. Virus culture:  
Recent studies have developed cell lines for the in-vitro culture of HEV. The 1st cell 
culture system to be used efficiently was PLC/PRF/5 derived from cells from human 
hepatocellular carcinoma cells. Other systems like A549 cells derived from human 
lung carcinoma have been used(53). Experimental studies of replication of HEV from 
animal sources (pig) in 3 dimensional (3D) culture with rotating wall vessel in human 
hepatoblastoma PLC/PRF/5 cells have been attempted with evidence of replication up 
to 5 months(54). Virus culture is time consuming, laborious, expensive, requires 
equipment and expertise hence not feasible for routine diagnostics. 
8.2. Detection of HEV nucleic acid:  
Molecular assays have an excellent sensitivity and specificity for the detection of 
current HEV infection. It is considered as the gold standard for the detection and 
confirmation of acute infection(55). Real time PCR assays and loop mediated 
isothermal amplification (LAMP) assay are available for the detection HEV RNA(56). 
The viremia in serum can be detected for 3-4 weeks after the onset of symptoms and 
in stool from 1 weeks prior to about 6 weeks after the onset of symptoms(57). The 
sensitivity of molecular assay depends on the time of presentation, time of specimen 
collection, transport and processing. An undetectable HEV RNA does not rule out the 
possibility of an infection(58). The duration of viremia and the fecal shedding of the 
virus is prolonged in immunocompromised(9). 
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Figure 3: Course of HEV infection and the markers for diagnosis 
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8.3. Antigen detection:  
HEV antigen can be detectable in serum even prior to the elevation of liver enzymes 
but decreases after the seroconversion(6). Enzyme immune assays (ELISA) are 
available for the detection of viral capsid protein (coded by the ORF 2 region). 
 A good correlation between antigen positivity and the presence of detectable nucleic 
acid has been demonstrated. The antigen is detectable in serum almost similar to the 
appearance of HEV RNA in the stool but disappears before that of HEV RNA.  
An Indian report on antigen detection showed a concordance of 66.6% (p 0.0206) 
between the HEV RNA and antigen with 100% detection in the first 3 days of illness 
with decline after 7 days, thus providing a possibility that HEV antigen can be used as 
an early diagnostic marker for HEV infection(59). HEV antigen detection can be 
considered as a cost effective alternative to HEV PCR in resource limited settings. 
Antigen detection can be used for HEV detection during the window period prior to 
seroconversion(8). 
 
8.4. Antibody detection:  
IgG, IgM and IgA antibodies can be demonstrated against HEV using various 
methods like immune electron microscopy, western blot and fluorescence blocking 
antibody assays in the past but the most commonly used format for detection is 
enzyme immune assay (ELISA).  
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IgG and IgM detection are available for seroprevalence studies and diagnosis of HEV 
respectively. IgM antibodies can be detected as early as 3-4 days after the onset of 
jaundice and can persist up to 5- 6 months or more while IgG antibodies appear 
shortly after IgM but remains for a longer period of time which varies from 14-20 
months to 8 years(6).   
8.4.1. Anti HEV IgG assay:  
These are the oldest serological tests that use structural and non-structural proteins 
expressed from ORF 2 region(60)(61) or synthetic peptides(62). The main stay for 
IgG detection is for epidemiological purposes. Its main role is as a marker for remote 
infection. Various epidemiological studies had used IgG antibody detection for 
estimating the seroprevalence of a particular geographic location. IgG antibody is seen 
even after years of being exposed or infected.  
 
8.4.2. Anti HEV IgM assay:  
Presence of IgM antibodies denote recent infection. Various in-house anti-HEV IgM 
antibody ELISA have been described(60)(63). Commercially available ELISAs, have 
wells coated with recombinant antigens from ORF 2 region of HEV (capsid antigen) 
for the detection of HEV IgM. An IgM capture (µ capture) ELISA eliminates false 
negative in the presence of a high IgG titres, thus increases the sensitivity and 
specificity of the assay(64). The IgM anti-HEV assays had a sensitivity of 72-98% and 
a specificity of 78-96% in a comparative study using in-house and commercial IgM 
antibody assays(65).  
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9. Treatment:  
Asymptomatic HEV infections can occur and are often self-limiting. Acute hepatitis E 
infection may require only supportive treatment like oral rehydration in an 
immunocompetent individual. Clearance of the infection can be altered if the host 
immune response is affected. Failure of viral clearance and chronic infections have 
been reported in patients with immune suppression. Reduction in the level of 
immunosuppression in case of solid organ transplant (SOT) recipients with chronic 
HEV infection resulted in clearance of the virus in 30% of patients(9).  
 
Anti-viral agents like ribavirin have been considered as a monotherapy in solid organ 
transplants and ACLF patients. A multicentre retrospective study case series with 59 
SOT recipients receiving 600mg daily for 3 months demonstrated a HEV (genotype 3) 
clearance of 95%. A sustained virological response (SVR) defined as undetectable 
HEV RNA at least 6 months after stopping ribavirin was seen in 78% as per the same 
study(10).  
Ribavirin therapy in ACLF have been studied in recent times. An Indian study on 4 
ACLF patients treated with 200-600mg of ribavirin for a duration of 3-24 weeks 
showed a viral clearance in 3-8 weeks with no documented relapse at 6 months follow 
up(11).  
The proposed mechanisms of action for ribavirin on HEV includes depletion of 
intracellular GTP reserves(66). Other mechanisms include immunomodulation, 
expression of interferon stimulated genes and inhibition of viral replicative machinery.   
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Antivirals are considered in patients in whom immunosuppressive therapy cannot be 
reduced or adequate viral clearance cannot be achieved even after decreasing the 
immune suppression(67). A mutation at G1634 in the RdRp domain of the ORF 1 
region is associated with treatment failure with ribavirin(68).  
Studies with other drug therapies like PEGylated interferon alpha had shown 
promising results(69).  
Immunosuppressive drugs commonly used like calcineurin inhibitors (cyclosporine, 
tacrolimus) have a stimulatory effect(70) while mycophenolate mofetil have an 
inhibitory effect on replication of HEV in vitro.(71)  
Sofosbuvir, a nucleotide analogue and inhibitor of RNA polymerase which was 
recently licensed in India for treatment of hepatitis C has been studied in-vitro for 
activity against genotype 3 HEV. The inhibition of viral replication was found to be 
an additive effect with ribavirin but further trials are needed for the same(72).  
 
10. Prevention:  
Adequate water safety is of prime concern for prevention of HEV in the developing 
counties. Properly treated water reduces the risk of water borne outbreaks. Vaccines 
for hepatitis E virus primarily aim at reducing the transmission during outbreaks. It 
would be useful in patients with underlying liver disease, pregnancy where the 
mortality rates due to hepatitis E infection are high(33). 
Two vaccines have been in human trial of which HEV 239 has been licensed in China 
for human use(73). 
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10.1. HEV 239 vaccine (Hecolin®): 
It is a recombinant HEV vaccine of amino acids 368-606 in the ORF 2 capsid protein 
from a HEV genotype 1 expressed in Escherichia coli. It is made up of virus like 
particle (VLP) assembled by expressed homodimers. It is sold under the trade name 
Hecolin® (Xiamen Innovax Biotech Co Ltd, China). It has completed the pre 
licensing clinical trials (phase I to III) and is now licensed in China for use in adults 
more than 16 years of age. Three doses of 0.5ml containing 30 µg of purified antigen 
in aluminium hydroxide (0.8mg) in buffered saline is given at 0, 1 and 6 month 
duration as an intramuscular injection(74). A phase 4 trial on efficacy of vaccine in 
elderly (above 65 years) is ongoing. After the phase III trial, the overall efficacy of the 
vaccine after 24 months was 79.2% (95% CI 67.7-86.6) (Zhu et al 2010) while long 
term efficacy of the vaccine in a 4.5 year duration was 86.8% (95% CI, 71 to 94)(12). 
 
 
10.2. 56 KDa protein vaccine (rHEV):  
It is a recombinant vaccine derived from the HEV genotype 1 (SAR55 Pakistani 
isolate) containing ORF 2 capsid (amino acid 112-607) expressed in insect cells using 
a baculovirus system manufactured by GlaxoSmithKein, Belgium. 20µg of antigen 
with aluminium hydroxide is given at 0, 1 and 6 months. The efficacy of the vaccine is 
96% (95% CI 86-99) after 1.5 years(74). The vaccine has not yet been licensed for 
use.  
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10.3. Other vaccine targets:  
Experimental vaccines with antigenic determinants like trpE C2 protein, pE2 protein, 
53 KDa protein, 62 KDa protein expressed in E.coli and insect cells with baculovirus. 
DNA vaccines have also been tried for HEV like pcHEVORF2 (Burmese strain of 
HEV genotype 1 ORF 2 protein) and the Lipo NE DP (Indian genotype 1 strain). 
These vaccines are still under construction and warrants further experiments and trials 
for assessing safety and efficacy (SAGE 2014).  
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11. A review on ACLF (cases) and chronic liver disease (controls) are 
considered below.  
11.1. Chronic liver disease (CLD): 
A condition in which the liver parenchyma undergoes progressive destruction 
over a period of more than 6 months causing fibrosis and regenerative nodules finally 
leading to scarring of liver accompanied by poor functioning of the liver resulting in 
cirrhosis (irreversible damage to the liver).  CLD accounts for over one million deaths 
in 2010, (2% deaths worldwide)(75).  
A state of compensation exists between the hepatocytes and the chronic 
inflammatory response thus remaining asymptomatic. Various factors have been 
associated as a causative agent for developing CLD. Both infective and non-infective 
causes have been attributed.  
Infective causes include hepatitis B virus which is still the most common cause 
of virus induced CLD in India followed by hepatitis C virus. Among the non-infective 
causes, alcohol is one of the leading cause for CLD. Non-alcoholic steatohepatitis 
(NASH) and non-alcoholic fatty liver disease (NAFLD) has a global prevalence of 
20%(76) and are considered as one of the major causes for CLD. Other causes include 
auto-immune aetiology, Wilson’s disease, hemochromatosis, toxin or drug induced 
and cryptogenic as a diagnosis of exclusion. Genetic polymorphisms and cofactors 
(obesity and alcohol) can act as risk factors leading to the progression of fibrosis.   
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11.2. Acute on chronic liver failure:  
A rapid decompensation of pre-existing chronic liver disease due to an acute 
precipitating factor often leading to an increased mortality is considered as an acute on 
chronic liver failure.  
Two schools of thought prevail between the western and the eastern countries 
prevail and common ground has not been reached. According to the APASL, ACLF is 
defined as “Acute hepatic insult manifesting as jaundice and coagulopathy, 
complicated within 4 weeks by ascites and/or encephalopathy in a patient with 
previously diagnosed or undiagnosed chronic liver disease associated with a high 
4-week mortality”(77).  
However, European Association for the Study of Liver (EASL) and American 
Association for the Study of Liver Disease (AASLD) defines ACLF as “an acute 
deterioration of pre-existing chronic liver disease usually related to a precipitating 
event and associated with increased mortality at 4 weeks due to multisystem organ 
failure”(78). 
The APASL criteria considers a time duration of 4 weeks between the acute insult and 
development of ACLF with a defined cut off for bilirubin (total bilirubin ≥5 mg/dl) 
and International standardized ratio (INR ≥1.5) or prothrombin activity (≤ 40%) for   
defining liver failure while even extrahepatic causes like sepsis and variceal bleed 
were considered as precipitating event as per EASL consensus(77).  
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The infectious causes of acute insult include hepatitis E virus which was seen in 21% 
of ACLF as a cause of decompensation(7).  HEV is a common trigger factor for 
ACLF in India. Other acute causes include hepatitis A, reactivation of hepatitis B and 
non-infectious causes like autoimmune flare, ischemic hepatitis, ethanol related 
decompensation and drug induced causes(77).   
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MATERIALS AND METHODS 
1.1. Study design: 
This is a prospective cross sectional study conducted at the Department of Clinical 
Virology, Christian Medical College and Hospital, Vellore. Blood and stool samples 
were collected from participants with a diagnosis of acute on chronic liver failure 
(ACLF) as cases and stable chronic liver disease (CLD) as controls over a period of 
18 months. A quantitative real time polymerase chain reaction (qPCR) for 
quantification of viral load in plasma and stools samples were evaluated, an HEV 
antigen ELISA (WANTAI, Beijing, China) for detection of viral antigens in serum 
and stool specimens, and comparison of IgM detection ELISA (MP Diagnostics) and 
IgM capture ELISA (WANTAI, Beijing, China) assays for anti-HEV antibodies in 
serum were employed.   
 
1.2. Ethics approval 
The approval for the study was obtained from the Institutional Review Board 
Christian Medical College and Hospital, Vellore (IRB Min No: 9196 dated 08-12-
2014).  
1.3. Study duration:  
This study was conducted over a period of 18 months from January 2015 to August 
2016.  
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1.4. Study sample:  
The study cases samples consists of blood and stool specimens collected from 
consented participants who were diagnosed as acute on chronic liver failure and 
admitted in ward. The same was collected from control participants with stable 
chronic liver disease who attend the liver clinic.  
1.4.1. Inclusion criteria: 
1. The ACLF case is defined using an APASL 2014 consensus as an acute hepatic 
insult manifesting as:  
(i). Jaundice (serum bilirubin >5 mg/dl) and coagulopathy (INR >1.5 or 
prothrombin activity <40 %) 
(ii). Complicated within 4 weeks by clinical ascites and/or encephalopathy in a 
patient with previously diagnosed or undiagnosed chronic liver disease or cirrhosis. 
(iii). Associated with a high 28-day mortality. 
2. Controls were stable CLD patients of any aetiology attending regular check-up in 
the out-patient basis.  
3. Individuals who gave consent to participate in the study.  
 
1.4.2. Exclusion criteria:  
1. Patients who are on interferon or ribavirin therapy.  
2. Patients not willing for consent. 
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Study algorithm 
 
 
 
 
 
 
 
 
 
 
 
 
  
Patients diagnosed as acute on chronic liver failure (ACLF) and chronic liver 
disease (CLD) who are admitted in medical wards 
 
   Informed consent taken and the patient Performa filled    
 
7ml of blood and a small amount (20-25 grams) of stool will be collected from 
the subject and transported at 4°C to the virology lab 
Plasma and stool will be aliquoted and stored at -
70°C until further testing  
RNA will be extracted from 
the plasma and stool of 
subjects using RNA 
extraction protocol (Qiagen) 
 
Plasma aliquot for IgM 
Anti HEV antibody 
detection 
Plasma and stool aliquot 
for hepatitis E antigen 
detection using a 
commercial assay 
detecting the viral protein 
The extracted RNA 
from plasma and stool 
will be subjected to a 
real time quantitative 
PCR using primers and 
probes and appropriate 
cycling conditions  
 
IgM anti HEV will be 
detected by two assays 
with varying principles 
(IgM capture ELISA and 
anti IgM antibody 
detection ELISA) 
Results of the various assays in ACLF cases will be compared with 
the HEV detection rates 
in patients with stable chronic liver disease (controls) 
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2.1. Processing of blood samples: 
After getting an informed consent, 7 ml of blood is collected in sterile vacutainer 
tubes containing potassium ethylene diamine tetra acetic acid (K2 EDTA) and are 
transported to the laboratory in ice containers at 4°C. The tube is centrifuged at 3000 
rpm for 10 minutes and the plasma is pipetted into a sterile tarson tubes. The separated 
plasma is then aliquoted as 600µl into pro-vials and are stored at -80°C until tested.  
2.2. Processing of stool samples: 
About 5-10 grams of stool is collected in a sterile, wide mouth, screw capped plastic 
container. A 20% suspension of the stool is made with 1% phosphate buffered saline 
(PBS) and vortexed thoroughly. The supernatant is then aliquoted as 600µl into pro-
vials and are stored at -80°C until tested.  
3.1. Extraction of the viral RNA: 
3.1.1. Materials required: 
QIAamp RNA Mini Kit (Qiagen, Hilden, Germany) containing: 
i. Lysis buffer (AVL) 
ii. Wash buffer 1 (AW1) 
iii. Wash buffer 2 (AW2) 
iv. Elution buffer(AVE) 
v. QIAamp Mini Spin Columns 
vi. Collection Tubes (2 ml)    
- 100% Ethanol  
- Calibrated pipettes: 10-1000µl and 20-200µl with appropriate sterile tips. 
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3.1.2. Procedure:  
RNA extraction was done using QIAamp RNA Minikit (spin coloumn) as per the 
instructions provided by the manufacturer.  
1. The samples and negative control are brought to the room temperature before 
initiating the extraction procedure.  
2. Carrier RNA provided by the manufacturer is reconstituted using 310µl of the 
elution buffer (AVE). 
3. Vial containing the carrier RNA is vortexed thoroughly and spin down.   
4. The spin downed contents (310µl) are then added to 31 ml of viral lysis buffer 
(AVL).  
5. The lysis buffer is vortexed thoroughly and is aliquoted as 560µl into 
Eppendorf tubes. These AVL can be stored at 4-8°C for later use.  
6. The AVL aliquots are brought to room temperature and vortexed until crystals 
are dissolved completely before use. 
7. 200µl of the plasma or stool supernatant is added to 560µl of lysis buffer, 
vortexed thoroughly and incubated at room temperature for 10 minutes.  
8. The Eppendorf is then centrifuged at 8,000rpm for 1 minute.  
9. 560µl of ethanol is added, vortexed and spin downed.  
10. 630µl of the contents in the Eppendorf is transferred in to the spin column and 
centrifuged at 8000rpm for 1 minute. 
11. The collecting tube is discarded into a jar and the spin column is transferred to 
a new collecting tube. 
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12. Remaining 630 µl is transferred into the spin column and centrifuged at 
8,000rpm for 1 minute  
13. The spin column is replaced into a new collecting tube and the prior is 
discarded. 
14. 500µl of the wash buffer (AW1) is added and centrifuged at 8,000rpm for 1 
minute.  
15. The spin column is replaced into a new collecting tube and the prior is 
discarded. 
16. 500µl of the wash buffer (AW2) is added and centrifuged at 14,000rpm for 3 
minutes.  
17. The spin column is transferred into a new collecting tube and the prior is 
discarded.  
18. 55µl of the elution buffer (AVE) is added and centrifuged at 8000rpm for 1 
minute.  
19. The spin column is discarded and the Eppendorf tubes containing the RNA 
extract is placed at 4-8°C for use within 1-2 hours and stored at -20°C for later 
use.  
 
3.2. RNA quantification: 
The real time PCR for the quantitation of HEV in both plasma and stool was from 
Fast Track Diagnostics (Qui-Si-Sana Seafront, Sliema SLM 3110, Malta).  
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3.2.1. Principle: 
A polymerase chain reaction was used for the amplification of a specific target in the 
HEV genome. The amplification occurs in real time and detected by using fluorescent 
probes which generates a curve. The commercially available assay contains three 
quantification standards (QS1- 3X104 IU/ml, QS2- 3X105 IU/ml and QS3- 3X106 
IU/ml) which were included in each run. HEV RNA, if present in the unknown sample 
can be quantified by extrapolation of the curve obtained with that of the standard 
curves.  
3.2.2. Master mix preparation 
The master mix was prepared in a clean room. The work bench was cleaned with 
100% ethanol before and preparing the master mix. The primers, probes, enzyme and 
buffer were brought to room temperature before use. The reagents are vortexed and 
spin downed.  
The volumes of the reagents used for one reaction are given in Table 3: 
Table 3: Reagents and its volumes for master mix preparation 
Reagent Volume 
Primers and probes (PP Mix) 1.5 µl 
Buffer 12.5 µl 
Enzyme 1 µl 
Total volume per reaction 15 µl 
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The master mix prepared was gently vortexed and spin downed. Direct light was 
avoided while preparing the master mix 
3.2.3. Reaction volume: 
15 µl of the master mix were aliquoted into flat capped reaction tubes in the “clean 
room”. 10 µl of the extract from negative control and the samples were added to the 
reaction tubes containing master mix. A final volume of 25 µl per reaction was 
attained. The standards provided by the manufacturer (QS1, QS2 and QS3) were 
included in every run for quantification.   
3.2.4. Cycling conditions: 
Rotor gene 3000 with a 36 rotor well from Corbett Research, Sydney, Australia. It 
uses an open platform for amplification. A protocol for cycling conditions was set 
using a software provided by the manufacturer.  
The temperature conditions set for each step is given in Table 4: 
  Table 4: Temperature and cycling conditions 
Step Temperature Time Number of 
cycles 
Reverse transcription 42°C 15 minutes 1 
Initial denaturation 94°C 3 minutes 1 
Cycling 94°C 
60°C 
8 seconds 
34 seconds 
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3.3. Antigen detection method:  
A commercially available 96 well antigen detection ELISA from Wantai (Beijing, 
China) was used.   
3.3.1. Principle: 
A qualitative method for the detection of viral capsid antigen from plasma and stool 
by using an enzyme immune assay. Anti HEV antibody against the structural proteins 
of ORF 2 (capsid) coated wells capture the antigen which can be detected using a 
conjugate, chromogen and a substrate. A colour develops which was read using a 
spectrometer.    
3.3.2. Materials required: 
The commercially available assay contains the following  
i. Polystyrene wells coated with rabbit anti HEV antibodies against capsid 
antigen 
ii. Positive and negative controls 
iii. Wash buffer (20X concentration) 
iv. Horse radish peroxidase (HRP) conjugate 
v. Chromogen A (urea peroxide solution) 
vi. Chromogen B (TMB-Tetra methyl Benzidine) 
vii. Stop solution (0.5M sulphuric acid) 
- 37°C incubator  
- Calibrated pipettes: 10-1000 µl and 20-200 µl with appropriate tips. 
- Discard jar 
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- Distilled water for preparation of working solution for wash buffer. 
- ELISA washer (Elx 50, BioTek) 
- ELISA reader (Epoch, BioTek) 
3.3.3. Procedure 
1. The samples to be tested and the reagents were brought to room temperature 
before starting the experiment. 
2. 100 µl of the negative controls were added in the first three wells (A1, B1 and 
C1). 
3. 100 µl of the positive control were added in the next two wells (D1 and E1). 
4. 100 µl of the sample were added in duplicates in the subsequent wells. 
5. The plate was covered and incubated at 37°C for 60 minutes. 
6. 20X concentrated wash buffer was diluted with distilled water to get a working 
solution of 1 in 20 dilution.  
7. After the incubation, the plate was washed using an automated ELISA washer 
with a diluted buffer for five times (soak time of 30-60 seconds).  
8. The plate was turned down over a blotting paper to remove any remaining 
wash buffer.  
9. 100 µl of the Horse radish peroxidase conjugated to monoclonal anti HEV 
antibody was added into each wells. 
10. The plate was covered and incubated at 37°C for 30 minutes.  
11. The plate was washed again using an automated ELISA washer with a diluted 
buffer for five times (soak time of 30-60 seconds).  
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12. 50 µl of the chromogen A containing urea peroxide solution (substrate) and 50 
µl of chromogen B (Tetra methyl Benzidine) were added, covered with an 
aluminium foil and incubated at 37°C for 15 minutes. 
13. 50 µl of stop solution containing 0.5 M sulphuric acid was added 
14. A yellow colour develops if the reaction was positive 
15. The absorbance was measured at 450nm with a reference wavelength of 630nm 
(dual wavelength spectrometer) within 10 minutes of adding the stop solution.  
16. The plate readings were taken using an ELISA reader and the optical density 
(OD) value was calculated for 450nm and 630nm.  
17. The difference between them was calculated as delta OD. 
18. The readings were calculated using a software provided by the manufacturer of 
the ELISA reader.   
 
3.3.4. Validity of the assay 
For a valid test, the delta OD value for the positive control should be ≥0.800 and the 
negative control should be <0.100 when read at 450/630nm.  
3.3.5. Calculation of the cut-off value: 
Mean of the three delta OD values for the negative controls were calculated. The Cut-
off value was obtained by adding the mean value with 0.12.  
Mean NC = NC1+NC2+NC3/3 
Cut-off value = Mean NC+0.12   
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3.3.6. Interpretation: 
The reactivity rate (RR) was calculated by dividing the sample OD value with that of 
the cut-off value. Interpretation for RR value for is given in Table 5.  
Table 5: Interpretation for RR value 
Reactivity rate (RR) Interpretation 
<1 Negative 
>1 Positive 
0.9-1.1 Borderline 
 
3.4. Antibody assays: 
Two different formats of anti HEV IgM antibody ELISAs were used. A µ-capture 
ELISA and an IgM detection were compared.  
3.4.1. IgM (µ-capture) ELISA: 
A commercially available 96 well IgM antibody capture ELISA from Wantai (Beijing, 
China) was used.   
3.4.1.1. Principle: 
 A qualitative method for the detection of IgM antibodies against HEV from plasma 
by using an enzyme immune assay. The IgM antibodies were captured using wells 
coated with antibodies to human IgM protein (µ chain).  The captured antibody was 
detected using a conjugate, chromogen and a substrate.  
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3.4.1.2. Materials required 
The commercially available assay contains the following  
i. Polystyrene wells coated with antibodies against human IgM protein.  
ii. Sample diluent (serum base, casein and sucrose) 
iii. Positive and negative controls 
iv. Wash buffer (20X concentration) 
v. Horse radish peroxidase (HRP) conjugate 
vi. Chromogen A (urea peroxide solution) 
vii. Chromogen B (TMB-Tetra methyl Benzidine) 
viii. Stop solution (0.5M sulphuric acid) 
- 37°C incubator  
- Calibrated pipettes: 10-1000 µl and 20-200 µl with appropriate tips. 
- Discard jar 
- Distilled water for preparation of working solution for wash buffer. 
- ELISA washer (Elx 50, BioTek) 
- ELISA reader (Epoch, BioTek) 
3.4.1.3. Procedure 
1. The samples to be tested and the reagents were brought to room temperature 
before starting the experiment. 
2. 100 µl of the sample diluent was added to all the wells needed. 
3. 10 µl of the negative controls were added in the first three wells (A1, B1 and 
C1). 
4. 10 µl of the positive control were added in the next two wells (D1 and E1). 
51 
 
5. 10 µl of the sample were added in duplicates in the subsequent wells. 
6. The plate was covered and incubated at 37°C for 30 minutes. 
7. 20X concentrated wash buffer was diluted with distilled water to get a working 
solution of 1 in 20 dilution.  
8. After the incubation, the plate was washed using an automated ELISA washer 
with a diluted buffer for five times (soak time of 30-60 seconds).  
9. The plate was turned down over a blotting paper to remove any remaining 
wash buffer.  
10. 100 µl of the Horse radish peroxidase conjugated with a recombinant HEV 
ORF 2 antigen was added into each wells. 
11. The plate was covered and incubated at 37°C for 30 minutes.  
12. The plate was washed again using an automated ELISA washer with a diluted 
buffer for five times (soak time of 30-60 seconds).  
13. 50 µl of the chromogen A containing urea peroxide solution (substrate) and 50 
µl of chromogen B (Tetra methyl Benzidine) were added, covered with an 
aluminium foil and incubated at 37°C for 15 minutes. 
14. 50 µl of stop solution containing 0.5 M sulphuric acid was added 
15. A yellow colour develops if the reaction was positive 
16. The absorbance was measured at 450nm with a reference wavelength of 630nm 
(dual wavelength spectrometer) within 10 minutes of adding the stop solution.  
17. The plate readings were taken using an ELISA reader and the optical density 
(OD) value was calculated for 450nm and 630nm.  
18. The difference between them was calculated as delta OD. 
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19. The readings were calculated using a software provided by the manufacturer of 
the ELISA reader.   
 
3.4.1.4. Validity of the assay: 
For a valid test, the delta OD value for the positive control should be ≥0.800 and the 
negative control should be <0.100 when read at 450/630nm.  
 
3.4.1.5. Calculation of the cut-off: 
Mean of the three delta OD values for the negative controls were calculated. The Cut-
off value was obtained by adding the mean value with 0.26.  
Mean NC = NC1+NC2+NC3/3 
Cut-off value = Mean NC+0.26 
 
3.4.1.6   Interpretation:  
The reactivity rate (RR) was calculated by dividing the sample OD value with that of 
the cut-off value. Interpretation for RR value is given in Table 6. 
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Table 6: Interpretation for RR value 
Reactivity rate (RR) Interpretation 
<1 Negative 
>1 Positive 
0.9-1.1 Borderline 
 
3.4.2. IgM detection ELISA: 
A commercially available 96 well IgM antibody ELISA M.P. Diagnostics HEV IgM 
ELISA 3.0 (Singapore) was used. 
3.4.2.1. Principle: 
A qualitative method for the detection of IgM antibodies against HEV from plasma by 
using an enzyme immune assay. The IgM antibodies were detected using wells coated 
with highly conserved ORF 2 epitope, a conjugate, chromogen and a substrate.  
3.4.2.2. Materials required 
The commercially available assay contains the following  
i. Polystyrene wells coated with highly conserved conformational ORF 2 epitope.  
ii. Sample diluent (Tris based saline solution, heat treated normal goat serum, 
bovine serum albumin and stabilizers) 
iii. Positive and negative controls 
iv. Wash buffer (20X concentration) 
v. Horse radish peroxidase (HRP) conjugate 
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vi. Tetra methyl Benzidine (TMB) substrate 
vii. Stop solution (1N hydrochloric acid) 
- 37°C incubator   
- Calibrated pipettes: 10-1000 µl and 20-200 µl with appropriate tips. 
- Discard jar 
- Distilled water for preparation of working solution for wash buffer. 
- ELISA washer (Elx 50, BioTek) 
- ELISA reader (Epoch, BioTek) 
 
3.4.2.3. Procedure  
1. The samples to be tested and the reagents were brought to room temperature before 
starting the experiment. 
4. 200 µl of the sample diluent was added to all the wells needed. 
5. 10 µl of the negative controls were added in the first three wells (A1, B1 and C1). 
6. 10 µl of the positive control were added in the next two wells (D1 and E1). 
7. 10 µl of the external quality control (EQC) prepared in-house were added in each 
run in duplicates. 
8. 10 µl of the sample were added in duplicates in the subsequent wells. 
9. The plate was covered and incubated at 37°C for 30 minutes. 
10. 20X concentrated wash buffer was diluted with distilled water to get a working 
solution of 1 in 20 dilution.  
11. After the incubation, the plate was washed using an automated ELISA washer 
with 300µl diluted buffer for six times.  
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12. The plate was turned down over a blotting paper to remove any remaining wash 
buffer.  
13. A working solution of HRP conjugate with 1:200 dilution was prepared with the 
sample diluent.  
14. 100 µl of the diluted HRP conjugated with a mouse monoclonal anti human IgM 
antibody was added into each wells. 
15. The plate was covered and incubated at 37°C for 30 minutes.  
16. The plate was washed again using an automated ELISA washer with 300 µl 
diluted buffer for six times.  
17. 100 µl of the Tetra methyl Benzidine was added, covered with an aluminium foil 
and incubated for 15 minutes at room temperature. 
18. 100 µl of stop solution containing 1N hydrochloric acid was added 
19. A yellow colour develops if the reaction was positive 
20. The absorbance was measured at 450nm with a reference wavelength of 630nm 
(dual wavelength spectrometer) within 10 minutes of adding the stop solution.  
21. The plate readings were taken using an ELISA reader and the optical density (OD) 
value was calculated for 450nm and 630nm.  
22. The difference between them was calculated as delta OD. 
23. The readings were calculated using a software provided by the manufacturer of the 
ELISA reader.   
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3.4.2.4. Validity of the assay: 
For a valid test, the delta OD value for the mean positive control should be ≥0.500 and 
the mean negative control should be ≤0.100 when read at 450/630nm. The delta OD of 
the EQC were also compared in each run with values within range for validation.  
 
3.4.2.5. Calculation of the cut-off: 
1. Mean of the three delta OD values for the negative controls were calculated. 
The Cut-off value was obtained by adding the mean value with 0.400.  
2. Mean NC = NC1+NC2+NC3/3 
3. Cut-off value = Mean NC+0.400 
 
3.4.2.6. Interpretation:  
The reactivity rate (RR) was calculated by dividing the sample OD value with that of 
the cut-off value. Interpretation for RR value is given in Table 7.  
Table 7: Interpretation for RR value 
Reactivity rate (RR) Interpretation 
<1 Negative 
>1 Positive 
0.9-1.1 Borderline 
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RESULTS 
1. Baseline characteristics:   
1.1. Age-wise distribution: 
A total of 100 participants (50 ACLF cases and 50 CLD controls) from 16 to 70 years 
of age were included. The age wise distribution of the study population is showed in 
Figure 4. 
 
Figure 4: Age-wise distribution ACLF (cases n=50) and CLD (controls n=50) 
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1.2. Gender-wise distribution:  
Of the 50 cases, 41 (82%) were males and 9 (18%) were females while among the 
controls, 40 (80%) were males and 10 (20%) females (p=0.799). Gender wise 
distribution of the study population is showed in Figure 5.  
 
 
Figure 5: Gender Wise Distribution cases (n=50) and controls (n=50) 
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1.3. Geographic distribution  
1.3.1. Cases: 
Majority of the cases (50%) were from Tamil Nadu followed by Andhra Pradesh 
(14%), West Bengal (12%) and Jharkhand (12%). Two cases (4%) were from Odisha 
and one case (2%) each from Kerala, Bihar, Chhattisgarh and Assam. The 
geographical distribution of cases are showed in Figure 6.  
 
 
Figure 6: Geographical distribution of cases (n=50) 
  
50%
14%
12%
12%
2%
4%
2% 2%
2%
Tamil Nadu Andhra Pradesh West Bengal Jharkhand Chhattisgarh
Odisha Assam Bihar Kerala
60 
 
1.3.2. Controls: 
Majority of the controls (34%) were from Tamil Nadu followed by West Bengal 
(22%), Jharkhand (12%) and Andhra Pradesh (10%). Two cases from Bihar (4%), one 
each from Telangana, Chhattisgarh and Madhya Pradesh (2%). Bangladesh 
contributed 12% of controls in this study. The geographical distribution of controls are 
showed in Figure 7.  
 
 
 Figure 7: Geographic distribution of controls (n=50)  
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2.1. Causes of underlying chronic liver disease among ACLF cases 
The most common cause of chronic liver disease among the cases was ethanol (60%) 
followed by cryptogenic aetiology (10%) and autoimmune causes of CLD (8%). 
Infectious causes included hepatitis B (6%) and Non Alcoholic Fatty Liver disease 
(NAFLD) seen in 6% of cases. Other minor causes includes Wilson’s disease (2%), 
Budd Chiari Syndrome (2%).  Dual causes for the underlying CLD were seen in 6% of 
cases of which all were due to ethanol and hepatitis B virus. The causes for underlying 
CLD among ACLF are showed in Figure 8.  
 
 
Figure 8: Causes of CLD among ACLF cases (n=50) 
 
60%
10%
8%
6%
6%
2%
2%
6%
 Ethanol Cryptogenic Autoimmune HBV NAFLD Wilson's disease BCS HBV + Ethanol
62 
 
2.2. Causes of underlying chronic liver disease among controls 
The most common cause of chronic liver disease among the controls was ethanol 
(24%). Hepatitis B virus contributed to 22% of the controls and was the second most 
common cause of CLD in this study. Other infective causes include hepatitis C virus 
(10%) of which all were genotype 3. Cryptogenic CLD causes were attributed to 20% 
of the controls.  
Other causes included Wilson’s disease (6%), idiopathic non-cirrhotic intrahepatic 
portal hypertension (NCIPH) 6%, autoimmune (4%), Non Alcoholic Fatty Liver 
disease (NAFLD) 2%, Extrahepatic Portal Vein Obstruction (EHPVO) 2%. Dual 
causes for the CLD with ethanol and hepatitis B was 4%. The causes for the 
underlying CLD among the controls are showed in Figure 9.  
 
 
 
 
 
 
 
 
 
 
 
 
63 
 
 
 
 
Figure 9: Causes of CLD among controls (n=50) 
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3. Biochemical parameters among cases and controls  
3.1. Total bilirubin and direct bilirubin levels (mg/dl): 
The serum total bilirubin and direct bilirubin levels between cases and controls were 
compared using the median and the interquartile range (IQR) (Figure 10). The median 
TB among cases were 19.2 mg/dl (IQR 11.3, 24) and controls were 1.10 mg/dl (IQR 
0.70, 2.0) (p<0.001). The median DB among cases were 13.85 mg/dl (IQR 8.1, 19.1) 
and controls were 0.44 mg/dl (IQR 0.2, 0.9) (p<0.001).  
 
Figure 10: Total and direct bilirubin levels (mg/dl) among cases and controls 
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3.2. Comparison of Aspartate transaminase (AST/SGOT) and Alanine 
transaminase (ALT/SGPT) between the cases and controls (IU/ml):  
The median AST among cases were 146 IU/ml (IQR 82, 207) and that of controls 
were 40 IU/ml (IQR 31, 63) (p<0.001). The median ALT among cases were 53.5 
IU/ml (IQR 25, 99) and that of controls were 27 IU/ml (IQR 19, 46) (p= 0.0003). 
Comparison between cases and controls are shown in Figure 11.  
 
 
Figure 11: Aspartate transaminase (AST) and Alanine transaminase (ALT) levels 
(IU/ml) among cases and controls 
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4. Causes of the acute insult among the ACLF cases 
The acute event most commonly attributed as an insult resulting in decompensation of 
pre-existing liver disease in this study was found to be ethanol (54%). HEV alone was 
the second leading cause of acute insult among ACLF (14%). Other minor causes 
were drug induced (8%) and malignancy like hepatocellular carcinoma (4%). There 
was one case each of hepatitis A infection, autoimmune hepatitis and sepsis leading to 
decompensation (2%). The cause of the acute injury was unknown in one patient.  
Dual causes had been considered in 6 cases of which, 6% was by ethanol and HEV, 
4% by drug induced hepatitis in an HBV related CLD and 2% by drug induced and 
autoimmune reactivation in an underlying autoimmune CLD. The various causes of 
acute insults among the ACLF leading to decompensation are depicted in Figure 12.  
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Figure 12: Acute insults among ACLF cases (n=50) 
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5. Results of the assays used for the diagnosis of hepatitis E virus among cases 
and controls: 
5.1. Real-time PCR assay (Fast Track Diagnostics, Qui-Si-Sana Seafront, Sliema 
SLM 3110, Malta): 
5.1.1. Plasma samples: 
A real time quantitative PCR assay on plasma samples showed one case positive for 
hepatitis E virus with a viral load of 403 IU/mL (ct value of 33.23). All our controls 
were negative for HEV RNA. The real time curve of the positive ACLF case for the 
plasma sample is given in Figure 13.  
 
Figure 13: Real time curve for the plasma sample positive for HEV RNA 
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5.1.2. Stool samples: 
A real time quantitative PCR assay on stool samples also showed positive for hepatitis 
E virus with a viral load of 2,790 IU/mL (ct value of 29.28) by the same case. All our 
controls were negative for HEV RNA.   
Three quantitative standards (commercial) and an in-house control were used in each 
run. The in-house control was a positive archival stool sample (2,982 IU/ml, ct = 
29.18) collected during a previous HEV study (Courtesy: Dr. Gagandeep Kang). The 
real time curve of the positive ACLF case for the stool sample along with the in-house 
positive matrix control is given in Figure 14.  
 
Figure 14: Real time curve for the stool sample positive for HEV RNA 
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5.2. Antigen detection ELISA (Wantai, Beijing, China): 
Reactivity rate (RR) is calculated as the ratio between the sample optical densities 
(delta OD) to the cut off value (CoV) for that assay. This calculation makes individual 
sample optical densities more comparable with each other, even if done across 
different assays.  
Reactivity rate (RR) = Delta OD of the sample / Cut-off value for that assay  
The readings were calculated as delta OD and were converted to RR for comparison 
between ELISA assays.  
5.2.1. Plasma sample:  
Antigen was detected in one ACLF case who showed a positive mean reactivity rate 
of 6.971 as compared to 0.249 (mean + 3SD) of all disease negatives (n=99). There 
was no positive antigen result demonstrated among the controls. The median reactivity 
rate for the controls were 0.079.  
5.2.2. Stool samples 
Antigen detection ELISA done on stool samples of all the ACLF cases showed a low 
positive for one case with a mean RR of 0.680 compared to the background of 0.149 
(mean + 3 SD) of all the cases that were negative and were of very low optical 
densities. The same patient was positive for plasma and stool HEV RNA, plasma 
antigen ELISA and both the antibody assays employed in this study.  
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5.3. Antibody assays  
5.3.1. IgM Antibody detection ELISA (M.P. Diagnostics HEV IgM ELISA 3.0, 
Singapore) 
Ten out of the 50 ACLF cases (20%) when compared to two out of 50 controls (4%) 
were positive for HEV by antibody detection ELISA.  
The median reactivity rate of HEV IgM positives among ACLF cases was 1.565 as 
compared to 0.199 in the negatives (n=40), while the median reactivity rate of HEV 
IgM positives among controls was 1.864 as compared to 0.177 among the negatives 
(n=48) (Figure 15). The mean RR for the IgM detection ELISA among the disease (+) 
population is 3.792 as compared to 0.861 (mean + 3 SD) for all disease (-). 
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Figure 15: Median reactivity Rate of HEV IgM antibody (MP diagnostics) among 
cases (n=50) and controls (n=50) 
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5.3.2. IgM Antibody capture ELISA (Wantai, Beijing, China):  
Five out of the 50 ACLF cases (10%) were positive for HEV, while only one out of 
the 50 controls (2%) was positive by IgM capture ELISA.  
The median reactivity rate of HEV IgM positives among ACLF cases was 8.187 as 
compared to 0.22 in the negatives (n=45) while only one of the control was positive 
by this assay with an RR of 1.922 as compared to 0.018 among the negatives (n=49). 
The mean RR for the IgM detection ELISA among the disease (+) population is 7.706 
as compared to 0.635 (mean + 3 SD) for all disease (-). 
.  
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6. Comparison of disease (+) and diseased (-) 
A positive result in any assay for hepatitis E virus (PCR, antigen or antibody ELISA) 
was considered as disease (+) and the ones who are negative by all four assays were 
considered as disease (-).  
Ten out of the 50 cases were positive for hepatitis E virus by any one or more of the 
four assays used, while two out of the 50 controls were positive for hepatitis E virus 
by IgM ELISA only (20% vs 4%) (p=0.0138). 
HEV alone was seen in 7 cases (14%) as an acute event decompensating CLD while 3 
cases (6%) were seen as a dual insult with HEV and ethanol among ACLF cases.  
HEV was seen in 2 controls (4%) with underlying HCV related CLD.  
The causes of underlying CLD among the diseased population (n=12) includes 3 cases 
of ethanol (25%), 2 cases of HBV and HCV each (17%) and one case of autoimmune 
liver disease, Budd-Chiari syndrome, Wilson’s disease, NAFLD and cryptogenic liver 
disease (8.20%). (Figure 16).  
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Figure 16: Causes of underlying CLD among disease (+) (n=12) 
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 6.1. Biochemical parameters between the disease (+) and disease (-): 
6.1.1. Comparison of total and direct bilirubin levels (mg/dl) among the disease 
(+) and disease (-): 
The median TB level in the diseased (+) (HEV positives) was 19.1 mg/dl (IQR 7.5, 
24) when compared to 3.05 mg/dl (IQR 0.91, 18.25) among disease (-) (HEV 
negatives) (p=0.0149). The median DB level in the disease (+) was 11 mg/dl (IQR 
4.05, 16.8) when compared to 1.5 mg/dl (IQR 0.4, 13) among the disease (-) 
(p=0.035). 
Comparison of total and direct bilirubin levels (mg/dl) among the disease (+) and 
disease (-) population are given in Figure 17.  
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Figure 17: Comparison of total and direct bilirubin levels (mg/dl) among the disease 
(+) and disease (-) 
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level in the disease (+) were 58.5 (IQR 30.5, 230.5) when compared to 33 IU/ml (IQR 
21, 60) among the disease (-) (p=0.028). The median AST and ALT levels between 
the disease (+) and the disease (-) are compared in Figure 18.  
 
Figure 18: Comparison of AST and ALT levels (IU/ml) among disease (+) and 
disease (-) 
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7.0. Comparison of causes of mortality among cases and controls:  
The overall mortality rate among the ACLF cases were 20% as compared to controls 
where no mortality was seen.  
The leading cause for the mortality was contributed by alcohol in this study.  
The causes for the underlying CLD among the cases who died were ethanol (80%) and 
cryptogenic (20%) while the acute decompensation was due to ethanol (70%), HEV 
(10%), drug or chemotherapy induced (10%) and sepsis (10%) (Figure 19). 
 
 
Figure19: Acute insults among ACLF cases that died (n=10) 
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8.0. Disease wise comparison of liver disease: 
8.1. Ethanol related liver disease: 
It was considered as the only acute insult leading to decompensation of pre-existing 
CLD in 54% of ACLF cases. Ethanol was the leading cause of chronic liver disease 
among cases (60%) and controls (24%).  
Among ethanol related cases in ACLF, the median total and direct bilirubin levels 
were 18.52 mg/dl and 12.4 mg/dl respectively, when compared to controls with 
ethanol related CLD with 2.15 mg/dl and 1.0 mg/dl respectively.   
The median AST and ALT among ACLF cases were 123.5 IU/ml and 33 IU/ml 
respectively while that of controls were 46.5 IU/ml and 29.5 IU/ml.  
The highest mortality rate was contributed by ethanol, being the most common cause 
of an acute event precipitating ACLF (70%) and the underlying liver disease (80%).   
There was no significant difference in the amounts of alcohol consumed by the cases 
and controls. Information on the duration of alcohol intake was not available for all 
the cases.  
 
8.2. HEV related liver disease:  
HEV was considered as an aetiology responsible for acute decompensation of CLD in 
20% of ACLF cases.  
Only one among the 50 ACLF (2%) cases viremia (403IU/ml) and antigenemia 
(positive by antigen ELISA, Wantai, Beijing, China) were demonstrated.  
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All ten out of 50 cases (20%) and two out of the 50 controls (4%) showed IgM 
positivity by MP diagnostics, Singapore. 
HEV alone was the cause of acute event precipitating ACLF in 14% of cases while a 
dual aetiology with HEV and ethanol was seen in 6% of cases.  
HEV contributed to 10% of mortality in this study.  
 
 
 
8.3. HEV and ethanol: 
Three ACLF cases was encountered in this study who had both HEV and ethanol as a 
cause of acute decompensation leading to ACLF with an underlying ethanol related 
CLD. 
All three were positive by IgM detection ELISA (MP diagnostics, Singapore) with a 
median reactivity rate of 1.42  
The average amount of alcohol consumed per day was 300ml among the three with a 
mean duration of 16.7 years, however no mortality was seen among this group in this 
study.  
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9. HBV related liver disease: 
9.1. HBV related chronic liver disease:  
The underlying chronic liver disease contributed by HBV alone was seen in 3 ACLF 
cases (6%) and 11 controls (22%).  Dual cause for CLD with both HBV and ethanol 
was seen in additional 3 case (6%) and 2 controls (4%).  
 
9.2. Infection with HEV on HBV: 
Two cases were positive for IgM HEV antibodies who had HBV as an underlying 
aetiology for liver disease. No evidence of reactivation of HBV was seen in both the 
cases.  
They were negative for any detectable HEV viremia and antigen in plasma or stool. 
Both of them presented in more than 7 days of illness. No mortality was seen in this 
study group.  
 
9.3. HBV and ethanol  
Three of the ACLF cases and two of the controls had both HBV and ethanol as the 
underlying aetiology without any evidence of HBV reactivation. 
Among the three cases, the cause for the acute decompensation was found to be 
ethanol in 2 cases and malignancy/portal vein thrombosis in the other. 
However, no mortality was seen in this group.  
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9.4. HBV and drug-induced hepatitis: 
Two ACLF cases had evidence of prior exposure to HBV by a positive anti HBc level 
and had a recent history of exposure to native or ayurvedic preparations. The cause for 
acute decompensation was attributed to be drug induced and no evidence of active 
HBV viremia was demonstrated in this group.  
No mortality was seen in this group.  
 
10. HCV related liver disease: 
10.1. HCV related chronic liver disease: 
The cause of the CLD for 5 controls (10%) were due to HCV. 
The median TB and DB levels of the controls were 1.4 mg/dl and 0.5 mg/dl while the 
median AST and ALT were 66 IU/ml and 48 IU/ml.  
No mortality among HCV cases were seen in this study. 
 
10.2. Infection with HEV on HCV 
Two out of the 5 controls with HCV related CLD showed IgM positivity for HEV. 
Both were positive by IgM ELISA (MP diagnostics) but only one was positive by 
both MP diagnostics and Wantai IgM ELISA.  
No mortality was seen in this group.  
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11. Cryptogenic liver disease: 
A total of 5 ACLF cases (10%) and 10 controls (20%) were attributed to be 
cryptogenic liver disease (aetiology is unknown).  
The median TB and DB levels among the cases were 19.8 mg/dl and 16.7 mg/dl 
compared to 0.8 mg/dl and 0.2 mg/dl among controls. 
The median AST and ALT levels among cases were 198 IU/ml and 131 IU/ml 
compared to 32.5 IU/ml and 21.5 IU/ml among controls.   
Cryptogenic liver disease contributed to 20% mortality among ACLF cases in this 
study.  
HEV was the cause of acute event precipitating ACLF in one case (positive by IgM 
antibody assay) which subsequently resulted in death.  
 
12. Autoimmune liver disease: 
In four out of 50 cases (8%) and two out of 50 controls (4%), the aetiology for CLD 
was due to autoimmune liver disease.  
All cases were positive for any one or more tests like ANA, DCT or autoimmune 
hepatitis markers (ANA, ASMA, AMA and LKM-1) and were considered to be of 
autoimmune aetiology.  
The median TB and DB levels among the cases were 18.62 mg/dl and 15 mg/dl 
compared to 3.1 mg/dl and 1.5 mg/dl among controls. 
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The median AST and ALT levels among cases were 216.25 IU/ml and 112.5 IU/ml 
compared to 50.5 IU/ml and 41 IU/ml among controls.   
No mortality was seen in this study.   
HEV was seen as an acute insult in one case with autoimmune liver disease but a 
possibility of autoimmune reactivation cannot be ruled out.  
 
 
 
13. Drug-induced hepatitis: 
Drugs were attributed as acute cause for decompensation in 4 of the ACLF cases 
(8%).  
The underlying chronic liver disease were one NAFLD and three cryptogenic cases. 
The drugs causing acute damage includes 2 ATT induced hepatitis, 1 ART induced 
hepatitis and a chemo/radio induced hepatitis in a post-operative woman with Ca 
Breast.  
The mortality rate for drug induced decompensation was 10% in this study.  
  
14. Drug-induced and autoimmune hepatitis 
There was one case of drug induced hepatitis (probable ATT induced) in a case of 
autoimmune liver disease, but a possibility of autoimmune reactivation could not be 
ruled out.   
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15. Comparison of time of presentation among the HEV positive ACLF cases: 
The earliest markers for viremia and antigenemia were demonstrated in one of the 
ACLF case who presented at the day 4 of illness, while all the antibody positives 
presented around a mean of 6.8 days (2.604-10.996 days). The time of presentation 
and the percentage of assay positivity is shown in Figure 20.  
 
 
Figure 20: Time of presentation and assay positivity 
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16. Comparison of reactivity rate among the various ELISAs employed for HEV 
detection:  
Antigen was positive in one ACLF case while antibody was positive in all 10 cases. 
Only five out of the 10 cases were positive by both IgM detection and µ-capture 
ELISA of which three had a significant difference in RR between them. The RR 
values of all the ELISA positive cases are compared in Figure 21.  
While the MP diagnostics ELISA picked up additional 5 patients, the Wantai ELISA 
yielded a high RR in 3 out of the 5 ACLF cases that were positive compared to the 
corresponding MP diagnostics. (Patient 3, patient 7 and patient 9).  
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Figure 21: RR of antigen and antibody ELISAs of all the positive cases 
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DISCUSSION 
Hepatitis E virus causes over 20 million infections annually with 56,600 deaths a year 
occurring worldwide(2). Its unique features of geographical distribution, transmission, 
clinical manifestations vary between the developed and the developing nations as 
evidenced by reports from various parts around the world(3).  
Genotype 1 predominates most of the central and south Asia including India. It is a 
common cause of acute hepatitis mostly from a water borne transmission. Several 
outbreaks have been reported in the past particularly from North India (13).   
India has the highest number of HEV outbreaks reported as per a recent systematic 
review on the global burden of HEV outbreaks in 2016 since its discovery(79).  
HEV varies in its clinical features ranging from asymptomatic infection, acute 
hepatitis, chronic or persistent infection to extra-hepatic manifestations like skin 
rashes and arthritis.  
In patients with pre-existing liver disease, HEV is believed to decompensate liver 
function leading to ACLF. It results in an increased mortality among CLD patients.  
This study was aimed as an expanded approach to developing a diagnostic test for the 
detection of HEV using assays with varying principles. We aimed to quantitate and/or 
detect HEV using multiple assays (HEV RNA PCR, HEV antigen ELISA and IgM 
antibody ELISAs) for the diagnosis of HEV infection among ACLF patients.  
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This is a prospective observational and a cross sectional study with 50 matched cases 
and controls collected over a period of one and a half years (January 2015 to August 
2016). 
Plasma and stool samples were used for RNA quantification and antigen detection 
while plasma antibodies were detected using both IgM detection and IgM (µ) capture 
ELISAs.  
The gender distribution among the cases and controls in this study were comparable 
(p=0.799) with most of the study population in the middle age group. The geographic 
distribution of the study population reflected a predominance of patients from Tamil 
Nadu (p=0.479). Other states include West Bengal, Andhra Pradesh and Jharkhand. 
Six of our controls were from Bangladesh.  
Overall, our cases and controls were age, gender matched and geographically 
comparable with most of the participants from Tamil Nadu.  
Very few studies have been undertaken on the effect of HEV on ACLF patients from 
Tamil Nadu and this is one of the first studies to be carried out with the aim of 
developing an appropriate and cost effective diagnostic assay for HEV detection and 
quantification in patients with ACLF.  
A retrospective study conducted in our centre in 2004 explored the outcomes in 
patients with severe decompensation of CLD. IgM ELISA was used which reported 9 
cases with HEV super-infection and an IgG ELISA detected a seroprevalence of 56% 
and 21%  among CLD and matched controls respectively(43).  
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Studies using molecular assays and other alternatives like antigen detection methods 
are still lacking from South India. Early detection of an HEV infection is of much 
importance in patients with CLD due to the risk of decompensation of liver function.  
Diagnostic assays that detect HEV earlier in infection are necessary to diagnose 
patients who are at risk of developing infection resulting in a high mortality. 
Molecular assays and antigen ELISA are direct methods generally used for detection 
of HEV.  
In this era where treatment options like ribavirin are becoming available and 
vaccinations had been licensed with good long term efficacy, robust tools for 
detection and quantification of HEV which are standardized becomes the need of the 
hour.  
In vulnerable population like patients with CLD and immunosuppression, HEV 
quantification will help in assessing the severity of the disease using viral load 
estimation. A universally acceptable standard unit (IU/ml) is necessary for setting up 
treatment cut-offs, to document viral clearance, detect relapse and to recognize 
treatment failure. A well standardized quantitative PCR with the ability to detect HEV 
across genotypes proves beneficial in understanding the dynamics of HEV infection 
and explore more treatment options.  
As per the manufacturers claim, the assay used in the present study had the capacity to 
detect all 4 genotypes of HEV 
There is a need for an international standard (IS) capable of detecting HEV of all 4 
genotypes to harmonize assays world-wide. Currently, an established WHO IS 
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containing genotype 3a HEV RNA (code number 6329/10) with 2,50,000 IU/ml units 
was made commercially available from Paul Ehrlich Institute (PEI)(80).  
In this study, the role of HEV was extensively studied as an acute event precipitating 
liver failure and was found to be in ten cases (20%) and two controls (4%) who were 
positive for HEV by any one or more of the assays used (p=0.0138). HEV was the 
most common infectious cause responsible for acute insult on a pre-existing CLD 
leading to decompensation.  
Similar studies in the past on HEV and ACLF had shown an incidence varying from  
8-75% with a median of 21%(7). A recent study from China in 2010 showed a higher 
incidence of HEV in ACLF cases (72%) where IgM and IgG ELISA were used for the 
detection of HEV infection. The mortality rate among ACLF patients for HEV was 
34% in the same study(81). 
Earlier studies from India on the impact of HEV on patients with ACLF has showed a 
wide range of detection rates (4-66%). An Indian study in 2004 from Lucknow 
showed a 44% positivity for HEV antibodies using IgM anti-HEV ELISA with a 
mortality of 14% among ACLF patients(82). Similar studies from the same centre, in 
2009 showed a 66% incidence of HEV using IgM HEV ELISA with a mortality of 
44% among ACLF(83) while the yet other in 2012, showed detection rate of HEV 
among 64% of  paediatric ACLF cases (84).  
Most of the studies conducted in India were reported based on IgM or IgG anti-HEV 
antibody positivity. Studies using HEV RNA PCR and antigen detection ELISA are 
being initiated.   
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A prospective study in 2007 on cirrhotic patients revealed that 28% of cases had 
superimposed HEV infection using reverse transcription and nested PCR with a 
mortality of 43%(85) 
In our study, we used real time HEV RNA PCR, antigen detection ELISA and two 
different IgM antibody ELISA with varying principles (antigen detection and µ-
capture ELISA) for the diagnosis of HEV infection in ACLF.  
An incidence of 20% positivity among ACLF cases in our study reflects the rates 
similar to that of earlier published studies (median 21%)(7).  
Plasma viremia was demonstrated in one ACLF case with a viral load of 403 IU/ml 
who also had viral shedding in the faeces with a load of 2,790 IU/ml. Being a cross 
sectional study, both blood and stool samples were collected at the same period of 
time which revealed a higher stool viral load than viremia. This may suggest a 
prolonged viral faecal shedding as compared to the duration of viremia in ACLF 
patients but follow up samples will be necessary to confirm this assumption. 
Circulating HEV antigens were also detected from the plasma of the same patient. 
This patient also had a higher signal in the HEV antigen detection ELISA applied to 
the stool sample. Thus, viremia, faecal shedding and antigenemia was demonstrated in 
the same case who presented on day 4 of illness.  
In previous publications from India, 100% positivity for HEV RNA and antigen was 
seen in patients presenting in the first three days of illness while the rates decreased to 
54% for HEV RNA detection and 88% for antigen detection by 7 days of illness 
respectively (59).  
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In this study there was 100% correlation between the antigen detection ELISA and the 
HEV RNA positivity in a patient who presented early in illness. Similar findings were 
seen in an Indian study which showed that HEV RNA and antigen detection assays 
were comparable in detecting early infections. 
Antigen detection methods are gaining popularity as a cost-effective alternative for 
HEV PCR in resource limited settings. Detection of HEV antigen in stool is a non-
invasive test for detection of HEV infection. Commercially available assays have been 
validated using plasma, serum and faecal specimens.  
Two out of the ten HEV cases presented at day 4 of illness at the earliest. In one of 
these patients HEV RNA and antigen positivity in this study coincided with the 
presentation of patient being early in illness. However, a larger sample size and 
longitudinal studies are required for demonstrating the duration of viremia and 
antigenemia to attribute significance in using molecular and antigen detection method 
as a diagnostic assay for clinical specimens.  
HEV antigen detection in stool needs to be further standardized. The overall 
absorbance (optical densities) of stool samples were much lower than corresponding 
plasma samples. Therefore, when we performed HEV antigen detection in stool, we 
constructed a cut-off using mean + 3 SD of all the stool samples that where negative 
for HEV antigenemia.   
One ACLF case had a stool antigen RR slightly higher than the constructed mean + 3 
SD cut-off who was also positive for HEV RNA, with a high RR values in plasma 
antigen and antibody ELISA.   
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These challenges with interpreting HEV antigen ELISA in stool may be due to the 
difference in the matrix used. The ELISA employed for the antigen detection contains 
commercial controls (positive and negative controls) which are serum based. Further 
studies need to be carried out which should be matrix matched to address this issue.  
The duration of viremia and faecal shedding is known to be protracted in patients with 
CLD and immunosuppression but the duration of antigenemia and fecal antigen 
shedding needs to be further investigated especially in patients known to have a 
chronic course of illness.  
HEV positive ACLF cases presented around a mean of 6.8 days (2.604-10.996 days) 
of which all were positive by IgM detection ELISA. Antibody positivity was 100% by 
4-7 days of illness and even later as shown in another Indian study(59).  
The time of presentation plays a vital role in the laboratory diagnosis of HEV. 
Detection of HEV viremia and viral shedding requires appropriate sample collected 
early in illness while IgM antibody detection takes about a week to be positive and 
can be detected later in illness.  
In our study, HEV RNA and antigen were detected early in illness (as early as day 4 
of illness). Antibody assays were positive from day 4 but was still demonstrated even 
after a week of illness.  
The MP diagnostic assay used was found to be more sensitive while the Wantai assay 
was more specific. The level of agreement between the antibody assays was 0.638 
(kappa value).   
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In MP diagnostics ELISA, the median RR of HEV positives in controls though 
appears higher than cases, needs to be interpreted with caution because there were 
only two HEV positives among controls.  
All 10 HEV positive ACLF cases were picked up by MP diagnostics (IgM detection 
assay) while only five out of the 10 cases were positive by both MP diagnostics and 
Wantai assay (µ capture assay).  Of the five positive cases, three of the cases had a 
higher RR value for µ capture ELISA compared to IgM detection ELISA.  
IgM capture ELISA plays a pivotal role since they exclusively detect IgM without 
detecting any HEV IgG which may be detected by other formats of ELISA increasing 
the false positives for IgM assay in other assay formats.    
The role of IgM antibody capture assay (Wantai, Beijing, China) needs to be further 
studied to understand its role in eliminating any false positives as compared to other 
IgM detection assays.  
A two tier testing strategy may be suggested using the more sensitive IgM detection 
assay for screening while the positive samples may be subjected to a IgM capture 
assay which tends to be more specific.  
IgG antibody assays are still used for seroprevalence studies but its role in detection of 
HEV in an acute presentation is limited. IgG antibody can be useful in screening the 
vulnerable population at risk of developing HEV infections with severe outcome who 
may benefit from a vaccine. It can be also used for evaluating the immune response 
due to the vaccine, when it becomes available.    
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This study aimed at diagnosing HEV as an important cause of acute event leading to 
ACLF but was found only in 20% of the cases while ethanol was the number one 
cause for underlying CLD and its acute decompensation leading to death. 
Alcohol alone was responsible for 3.3 million deaths world every year wide (5.9%). 
Harmful use of alcohol had been associated with more than 200 disease and alcohol 
related injuries. Among all deaths in the 20-39 years age group 25% of deaths were 
related to ethanol use(86). Despite its harmful effects, alcohol had been in use for a 
very long period of time with an annual alcohol consumption globally of 38.3% as per 
WHO in 2012. India had been one of the top consumers of alcohol in 2010 with 30% 
of its population imbibing alcohol regularly. Heavy or binge drinking was a practice 
among some cultures worldwide which was estimated to be 16% globally, while 11% 
of the population indulged in such heavy drinking in India(87). An updated report 
from 2014 revealed 62 million alcohol users of which 17% were alcohol dependant in 
India(88). The mortality among ACLF was primarily contributed by ethanol alone as a 
precipitating factor, accounting for 70% of deaths.  
Hepatitis E accounted for 10% of mortality in this study while similar studies from 
India among HEV and ACLF reported a median short term mortality of 34%(7). 
HEV infections among CLD patients leading to ACLF resulting in an increased 
mortality warrants robust laboratory methods for rapid and accurate detection of HEV. 
Since the viremia is short lived, early presentation of the patient is necessary for the 
detection of HEV in plasma.  
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Detection of HEV RNA in the stool is a non-invasive alternative and can be detected 
for at least 1-2 week after the viremia is settled(57).  Protracted faecal shedding of the 
virus can occur in patients with CLD, which make stool a useful specimen for 
detection of HEV even if the patient presents after the early and brief viremia. In 
patients with immunosuppression where antibody production is impaired, detection of 
viral RNA in plasma or stool is the most efficient and accurate means of diagnosing 
HEV infection.   
Published literature showed distinct geographic distribution of various genotypes with 
genotype 1 being more common in India. Circulating genotype 4 exists among swine 
in India. Genotyping the HEV virus encountered in this study may shed light on the 
circulating strains contributing to ACLF. It is also important for assessing the ability 
of the various assays employed in detecting genotype 1 which is more prevalent in our 
region.  
Antigen detection ELISA is a cheaper and relatively rapid test when compared to 
molecular detection methods. Antigen detection can be of value in resource limited 
settings where it can be a cost-effective alternative to PCR in our country.  
IgM antibody is commonly used in many settings for the diagnosis of HEV infection 
which is simple to perform, rapid and cheap compared to molecular methods. IgM 
antibody denotes recent infection which can be detected as early as 3-4 days from the 
onset of jaundice and can be detected up to 5-6 months or more. It can be used as a 
diagnostic assay when the patients present later in illness after the viremia or faecal 
shedding of virus has been cleared. Its role in ACLF needs to be studied further.  
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Disadvantages of IgM detection methods include false negative results in patients who 
present early in illness and those with immunosuppression, and varying sensitivity and 
specificity among the different commercially available antibody assays due to the 
different principles used for IgM detection (detection ELISA, capture ELISA or ICT). 
Effective antivirals like ribavirin, sofosbuvir and PEGylated interferon have been used 
in trials for use against HEV infection.  In transplant recipients and ACLF patients, 3 
months therapy with ribavirin have shown promising results with documented 
evidence of viral clearance (10, 11).  
Establishing a quantitative HEV RNA PCR as a diagnostic assay is necessary for 
quantification of viral load in a specimen. At this age of promising antiviral agents in 
the horizon, it is beneficial to document viral loads to demonstrate the actual reduction 
of viral load or clearance of virus in response to treatment.  
Prevention of hepatitis E includes proper sanitation, good hygiene and control 
measures for safe drinking water. Awareness of hepatitis A and hepatitis B with 
delivery of these vaccines among CLD patients has decreased the incidence of these 
infections among CLD population. HEV is a novel agent with the ability to cause 
ACLF.  
Currently there is no licenced vaccine or standardized treatment protocols in India. A 
vaccine recently licensed in China (Hecolin®) has promising long term efficacy. Such 
vaccines may be beneficial to patients with CLD in our country who are at a risk of 
developing ACLF with an increased mortality.  
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LIMITATIONS 
1. As many of the ACLF patients in our study presented in ≥ 6 days of illness, 
there is a possibility that we could have missed the periods of brief viremia and 
antigenemia.  .  
 
2. This was a cross sectional study where patients were tested at a single point of 
time, however longitudinal studies are needed to assess the usefulness of all the 
markers in an extended time frame.  
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CONCLUSION 
This is the first study that has evaluated the role of all three HEV markers (RNA, 
antigen and antibody) in ACLF patients. The study has clearly shown a significant 
role of HEV in the aetiology of ACLF in chronic liver disease patients in comparison 
to stable chronic liver disease patients.  
Hepatitis E virus was the most common infectious cause of acute decompensation of 
chronic liver disease with an incidence of 20% and a mortality of 10% in this study.  
Ethanol consumption however is the single most frequent cause of chronic liver 
disease, also contributing to ACLF in patients from India. Ethanol was the leading 
cause of mortality in ACLF cases in this study.  
Based on the role of HEV in ACLF as demonstrated in this study, there is a need for 
establishing good diagnostic tests to identify HEV infection as early as possible and a 
need for vaccination among chronic liver disease patients.  
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ANNEXURES 





MP  RR 1 MP RR 2 Wan Ab 1 Wan Ab 2 Wan RR 1 Wan RR 2 SGOT SGPT Outcome 
Wantai RR 1 Wantai RR 2 Mean RR
HEV001 Neg 1.254 1.193 1.2235 0.071 0.071 0.071 0.126 0.156 0.141 0.038 0.03 0.034 21.02 16.9 121 46 ALIVE
HEV002 Neg 10 9.517 9.7585 8.917 7.456 8.1865 0.052 0.044 0.048 0.046 0.038 0.042 29 17.1 79 63 ALIVE
HEV003 Neg 1.532 1.498 1.515 0.731 0.799 0.765 0.06 0.08 0.07 0.038 0.046 0.042 19.1 12.4 198 26 ALIVE
HEV004 Pos 10.049 9.544 9.7965 7.764 7.539 7.6515 6.32 7.622 6.971 0.653 0.707 0.68 19.09 16 941 258 ALIVE
HEV005 Neg 0.606 0.546 0.576 0.022 0.018 0.02 0.176 0.147 0.1615 0.053 0.046 0.0495 19.8 17.1 119 34 ALIVE
HEV006 Neg 0.074 0.056 0.065 0.033 0.025 0.029 0.071 0.055 0.063 0.038 0.046 0.042 16.6 10.3 198 152 DAMA
HEV007 Neg 0.017 0.017 0.017 0.011 0.007 0.009 0.075 0.12 0.0975 0.038 0.061 0.0495 28.3 24 207 31 ALIVE
HEV008 Neg 0.27 0.28 0.275 0.079 0.071 0.075 0.082 0.12 0.101 0.03 0.038 0.034 8 5 68 7 DAMA
HEV009 Neg 0.579 0.546 0.5625 0.018 0.022 0.02 0.08 0.067 0.0735 0.084 0.076 0.08 18.94 15.9 348 226 ALIVE
HEV010 Neg 0.894 0.837 0.8655 0.034 0.011 0.0225 0.12 0.067 0.0935 0.038 0.097 0.0675 15 9.5 88 53 ALIVE
HEV011 Neg 0.08 0.047 0.0635 0.011 0.007 0.009 0.073 0.087 0.08 0.103 0.051 0.077 27.8 23.7 301 194 DAMA
HEV012 Neg 0.002 0.01 0.006 0.015 0.011 0.013 0.093 0.154 0.1235 0.09 0.045 0.0675 20.3 15.9 262 95 ALIVE
HEV013 Neg 0.378 0.304 0.341 0.018 0.015 0.0165 0.06 0.08 0.07 0.045 0.032 0.0385 11.1 9.8 152 24 EXPIRED
HEV014 Neg 0.23 0.215 0.2225 0.094 0.094 0.094 0.1 0.1 0.1 0.045 0.038 0.0415 38.4 34.8 119 97 DAMA
HEV015 Neg 0.039 0.054 0.0465 0.026 0.026 0.026 0.06 0.046 0.053 0.071 0.116 0.0935 4.2 3.1 62 15 EXPIRED
HEV016 Neg 1.464 1.769 1.6165 0.57 0.57 0.57 0.06 0.06 0.06 0.03 0.038 0.034 4.5 1.5 62 19 ALIVE
HEV017 Neg 0.148 0.309 0.2285 0.015 0.007 0.011 0.046 0.053 0.0495 0.032 0.038 0.035 33.7 31.8 116 25 DAMA
HEV018 Neg 0.259 0.193 0.226 0.015 0.019 0.017 0.053 0.053 0.053 0.025 0.038 0.0315 24 20.2 151 33 ALIVE
HEV019 Neg 0.159 0.208 0.1835 0.015 0.007 0.011 0.039 0.039 0.039 0.045 0.045 0.045 3.8 3.2 736 131 EXPIRED
HEV020 Neg 0.389 0.392 0.3905 0.011 0.015 0.013 0.373 0.357 0.365 0.045 0.045 0.045 19.3 12.4 141 39 EXPIRED
HEV021 Neg 0.234 0.169 0.2015 0.219 0.215 0.217 0.039 0.047 0.043 0.032 0.09 0.061 13.6 11.9 143 33 ALIVE
HEV022 Neg 0.536 0.541 0.5385 0.068 0.064 0.066 0.055 0.087 0.071 0.025 0.032 0.0285 11.3 8.1 149 99 ALIVE
HEV023 Neg 0.735 0.512 0.6235 0.037 0.049 0.043 0.031 0.047 0.039 0.019 0.032 0.0255 30.5 18.6 172 68 EXPIRED
HEV024 Neg 1.115 1.009 1.062 12.034 11.486 11.76 0.251 0.16 0.2055 0.13 0.046 0.088 26.6 16.7 3918 830 EXPIRED
HEV025 Neg 0.666 0.685 0.6755 0.049 0.045 0.047 0.03 0.038 0.034 0.012 0.032 0.022 23.8 22.5 175 80 ALIVE
HEV026 Neg 0.091 0.098 0.0945 0.015 0.011 0.013 0.047 0.055 0.051 0.032 0.032 0.032 9.6 6.68 56 21 ALIVE
HEV027 Neg 2.625 2.717 2.671 0.736 0.969 0.8525 0.097 0.12 0.1085 0.046 0.053 0.0495 32.9 30.09 142 250 ALIVE
HEV028 Neg 0.059 0.056 0.0575 0.007 0.001 0.004 0.019 0.025 0.022 0.038 0.032 0.035 6.3 3.9 71 20 ALIVE
HEV029 Neg 0.009 0.029 0.019 0.015 0.011 0.013 0.115 0.102 0.1085 0.025 0.025 0.025 22.5 18.8 68 24 DAMA
HEV030 Neg 0.113 0.098 0.1055 0.026 0.026 0.026 0.506 0.448 0.477 0.038 0.051 0.0445 8.9 5.7 49 24 EXPIRED
HEV031 Neg 0.077 0.079 0.078 0.019 0.015 0.017 0.147 0.134 0.1405 0.032 0.038 0.035 30.1 22.8 196 72 EXPIRED
HEV032 Neg 0.209 0.187 0.198 0.007 0.007 0.007 0.044 0.051 0.0475 0.038 0.038 0.038 25.8 23 235 114 ALIVE
HEV033 Neg 0.201 0.201 0.201 0.015 0.015 0.015 0.192 0.41 0.301 0.038 0.045 0.0415 19.6 17.2 225 96 DAMA
HEV034 Neg 0.046 0.075 0.0605 0.015 0.015 0.015 0.153 0.051 0.102 0.032 0.045 0.0385 19.9 17.5 104 18 ALIVE
HEV035 Neg 0.514 0.467 0.4905 0.007 0.011 0.009 0.038 0.025 0.0315 0.032 0.032 0.032 24.9 20 227 77 EXPIRED
HEV036 Neg 0.026 0.058 0.042 0.015 0.019 0.017 0.057 0.025 0.041 0.038 0.058 0.048 18.1 9.8 116 62 EXPIRED
HEV037 Neg 0.258 0.176 0.217 0.022 0.007 0.0145 0.032 0.048 0.04 0.019 0.038 0.0285 25 14 264 135 DAMA
HEV038 Neg 0.044 0.037 0.0405 0.081 0.022 0.0515 0.32 0.152 0.236 0.071 0.051 0.061 23.16 21.5 162 41 DAMA
HEV039 Neg 1.004 1.038 1.021 1.742 1.84 1.791 0.032 0.024 0.028 0.053 0.053 0.053 21.4 9.6 74 73 ALIVE
HEV040 Neg 0.1 0.075 0.0875 0.06 0.064 0.062 0.048 0.224 0.136 0.038 0.064 0.051 23 19.1 283 262 DAMA
HEV041 Neg 0.273 0.263 0.268 0.045 0.037 0.041 0.112 0.064 0.088 0.038 0.116 0.077 12.4 10.9 197 133 ALIVE
Ct 
Value 
Study 
No.
MP Ab RR 
(Average)
Wantai Ag RR 
(Average)
Wantai Ab RR 
(Average)
Stool Antigen ELISA Total 
bilirubin
Direct 
bilirubin
HEV042 Neg 0.131 0.133 0.132 0.018 0.026 0.022 0.048 0.04 0.044 0.038 -0.006 0.016 23.65 19.9 60 22 ALIVE
HEV043 Neg 9.39 9.562 9.476 14.905 14.95 14.9275 0.04 0.072 0.056 0.038 0.023 0.0305 10.5 8.1 153 54 ALIVE
HEV044 Neg 0.085 0.08 0.0825 0.034 0.034 0.034 0.04 0.04 0.04 0.123 0.058 0.0905 5.7 3.7 69 22 DAMA
HEV045 Neg 1.365 1.289 1.327 0.377 0.411 0.394 0.032 0.064 0.048 0.038 0.046 0.042 10.7 6.5 323 211 ALIVE
HEV046 Neg 0.07 0.07 0.07 0.022 0.022 0.022 0.088 0.09 0.089 0.032 0.038 0.035 3.2 2.6 169 52 DAMA
HEV047 Neg 0.816 0.571 0.6935 0.018 0.026 0.022 0.186 0.059 0.1225 0.032 0.071 0.0515 15.4 13.7 126 59 DAMA
HEV048 Neg 0.37 0.41 0.39 0.207 0.188 0.1975 0.055 0.055 0.055 0.025 0.448 0.2365 18.4 13.6 82 29 ALIVE
HEV049 Neg 0.745 0.891 0.818 0.026 0.026 0.026 0.804 0.097 0.4505 0.071 0.071 0.071 16 9.4 52 14 ALIVE
HEV050 Neg 0.178 0.219 0.1985 0.03 0.03 0.03 0.031 0.047 0.039 0.038 0.038 0.038 11.7 6.2 92 51 DAMA
MP  RR 1 MP RR 2 Wan Ab 1 Wan Ab 2 Wan RR 1 Wan RR 2 SGOT SGPT
HEV051 Neg 0.233 0.215 0.224 0.223 0.208 0.2155 0.067 0.082 0.0745 0.7 0.2 34 22
HEV052 Neg 0.373 0.318 0.3455 0.018 0.015 0.0165 0.082 0.082 0.082 0.67 0.33 66 48
HEV053 Neg 0.157 0.181 0.169 0.015 0.007 0.011 0.08 0.067 0.0735 5.5 2.7 61 36
HEV054 Neg 0.063 0.099 0.081 0.007 0.011 0.009 0.06 0.087 0.0735 0.92 0.48 76 30
HEV055 Neg 0.35 0.183 0.2665 0.007 0.015 0.011 0.093 0.14 0.1165 3.1 2.1 199 119
HEV056 Neg 0.11 0.103 0.1065 0.011 0.018 0.0145 0.154 0.08 0.117 1.1 0.4 60 33
HEV057 Neg 0.267 0.143 0.205 0.261 0.28 0.2705 0.194 0.1 0.147 0.39 0.2 18 14
HEV058 Neg 0.012 0.032 0.022 0.015 0.011 0.013 0.093 0.08 0.0865 0.8 0.2 29 21
HEV059 Neg 0.376 0.225 0.3005 0.007 0.011 0.009 0.087 0.147 0.117 1.6 0.6 54 17
HEV060 Neg 0.157 0.242 0.1995 0.011 0.011 0.011 0.06 0.1 0.08 0.6 0.1 40 60
HEV061 Neg 0.174 0.196 0.185 0.015 0.011 0.013 0.067 0.067 0.067 3 1.5 111 49
HEV062 Neg 2.141 2.354 2.2475 0.191 0.168 0.1795 0.067 0.082 0.0745 3 1.6 54 35
HEV063 Neg 0.462 0.172 0.317 0.007 0.011 0.009 0.214 0.04 0.127 1.4 0.5 98 97
HEV064 Neg 0.055 0.06 0.0575 0.019 0.007 0.013 0.08 0.067 0.0735 2.4 1 34 19
HEV065 Neg 0.069 0.07 0.0695 0.011 0.011 0.011 0.053 0.046 0.0495 1.4 0.6 51 34
HEV066 Neg 0.155 0.167 0.161 0.011 0.03 0.0205 0.053 0.046 0.0495 1.1 0.5 44 57
HEV067 Neg 0.087 0.118 0.1025 0.015 0.015 0.015 0.031 0.047 0.039 0.7 0.38 80 82
HEV068 Neg 0.062 0.06 0.061 0.397 0.393 0.395 0.031 0.063 0.047 1.3 0.4 32 26
HEV069 Neg 0.01 0.027 0.0185 0.018 0.011 0.0145 0.119 0.063 0.091 0.4 0.1 30 28
HEV070 Neg 0.083 0.055 0.069 0.015 0.018 0.0165 0.047 0.055 0.051 0.5 0.2 23 7
HEV071 Neg 0.487 0.44 0.4635 0.011 0.015 0.013 0.019 0.044 0.0315 0.6 0.2 29 17
HEV072 Neg 0.165 0.253 0.209 0.015 0.015 0.015 0.051 0.057 0.054 1.4 0.9 38 17
HEV073 Neg 0.167 0.174 0.1705 0.011 0.011 0.011 0.038 0.192 0.115 0.6 0.3 28 9
HEV074 Neg 0.571 0.721 0.646 0.011 0.011 0.011 0.03 0.03 0.03 1.7 1 119 38
HEV075 Neg 0.681 0.447 0.564 0.072 0.072 0.072 0.044 0.057 0.0505 0.9 0.2 29 18
HEV076 Neg 0.124 0.131 0.1275 0.011 0.011 0.011 0.038 0.153 0.0955 1.4 0.4 41 23
HEV077 Neg 0.835 0.679 0.757 0.791 0.791 0.791 0.062 0.046 0.054 2.7 1.3 76 28
HEV078 Neg 0.149 0.146 0.1475 0.015 0.015 0.015 0.101 0.039 0.07 0.9 0.6 33 32
HEV079 Neg 0.039 0.111 0.075 0.022 0.022 0.022 0.156 0.054 0.105 2 0.5 35 34
HEV080 Neg 0.144 0.089 0.1165 0.026 0.026 0.026 0.062 0.054 0.058 2.5 1.3 31 20
HEV081 Neg 0.228 0.194 0.211 0.022 0.026 0.024 0.078 0.078 0.078 3.1 0.9 36 18
HEV082 Neg 0.111 0.089 0.1 0.018 0.018 0.018 0.039 0.054 0.0465 0.6 0.2 31 24
HEV083 Neg 0.594 0.642 0.618 0.128 0.135 0.1315 0.046 0.046 0.046 0.8 0.4 18 10
HEV084 Neg 0.211 0.156 0.1835 0.022 0.018 0.02 0.062 0.062 0.062 2.5 0.8 38 15
HEV085 Neg 0.065 0.047 0.056 0.018 0.022 0.02 0.054 0.054 0.054 0.3 0.1 24 19
HEV086 Neg 0.151 0.226 0.1885 0.03 0.033 0.0315 0.078 0.125 0.1015 2.6 1.2 46 22
HEV087 Neg 0.16 0.177 0.1685 0.018 0.018 0.018 0.046 0.062 0.054 0.7 0.2 288 364
HEV088 Neg 0.554 0.584 0.569 0.483 0.43 0.4565 0.054 0.109 0.0815 0.7 0.3 40 46
HEV089 Neg 1.612 1.352 1.482 1.811 2.033 1.922 0.054 0.046 0.05 0.8 0.5 63 26
HEV090 Neg 0.219 0.206 0.2125 0.026 0.022 0.024 0.078 0.046 0.062 1.6 0.7 71 59
HEV091 Neg 0.056 0.056 0.056 0.018 0.018 0.018 0.046 0.046 0.046 1.4 0.6 133 59
Wantai Ag 
RR 
Total 
bilirubin
Direct 
bilirubinStudy No. Ct Value 
MP Ab RR 
(Average)
Wantai Ab 
RR 
HEV092 Neg 0.437 0.341 0.389 0.026 0.026 0.026 0.046 0.046 0.046 1.9 0.5 47 60
HEV093 Neg 0.06 0.07 0.065 0.022 0.018 0.02 0.054 0.07 0.062 0.4 0.2 27 9
HEV094 Neg 0.055 0.052 0.0535 0.856 0.856 0.856 0.765 0.117 0.441 0.8 0.2 22 19
HEV095 Neg 0.192 0.238 0.215 0.026 0.049 0.0375 0.054 0.046 0.05 0.6 0.2 43 52
HEV096 Neg 0.138 0.103 0.1205 0.049 0.052 0.0505 0.054 0.054 0.054 0.8 0.2 37 22
HEV097 Neg 0.11 0.04 0.075 0.026 0.022 0.024 0.078 0.054 0.066 0.6 0.2 20 10
HEV098 Neg 0.277 0.309 0.293 0.018 0.022 0.02 0.054 0.25 0.152 1.2 0.4 40 32
HEV099 Neg 0.633 0.476 0.5545 0.026 0 0.013 0.054 0.054 0.054 2.5 1.5 59 26
HEV100 Neg 0.438 0.453 0.4455 0.022 0.018 0.02 0.062 0.046 0.054 3.9 2.2 93 42
